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5α-RII 5-alpha reductase type II 
5-LOX 5-Lipo-oxygenase 
ADT Androgen deprivation treatment 
AF Activation function 
AI Androgen insensitive 
APCs Antigen presenting cells 
Api  70% ethanolic Alpinia oxyphylla extract 
Aquil 70% ethanolic Aquilaria sinensis extract 
AR Androgen receptor 
ARA Androgen receptor associated proteins 
ARE Androgen response elements 
AS Androgen sensitive 
Astra Aqueous Astragalus membranaceus extract 
BCL-2 
BPH 
B-cell lymphoma 2 
Benign prostatic hyperplasia 
COX Cyclo-oxygenase 
CSS Charcoal stripped serum 
CZ Central zone 
DBD DNA binding domain 
DHEA Dehydroepiandrosterone 
DHT Dihydrotestosterone 
EGF Epidermal growth factor 
ER Estrogen receptors 
EtOH Ethanol 
FBS Fetal bovine serum 
FGF Fibroblast growth factor 
FSH Follicle stimulating hormone 
GF Growth factor 
HSP Heat shock proteins 
IGF Insulin growth factor 
IL Interleukin 
KGF Keratinocyte growth factor 
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KO 
 
Knock-out 
LBD Ligand binding domain 
LTB4 Leukotriene B4 
LUTS Lower urinary tract symptoms  
MAPK Mitogen-activated protein kinase 
NSAID 
P 
Non-steroidal anti-inflammatory drug 
Promoter 
P9605 96% ethanolic Piper cubeba extract 
PC Prostate cancer 
PGE2 Prostaglandin E2 
PIN Prostatic intraepithelial neoplasia 
PKA Protein Kinase A 
PKC Protein Kinase C 
PSMA Prostatic specific membrane antigen 
PTEN Phosphatase and tensin homolog 
PZ Peripheral zone 
rmt Room temperature 
SHBG Sex hormone binding globulin 
SQM Squamous metaplasia 
TFA Trifluoroacetic acid 
TGF-β Β-Transforming growth factor 
TNF Tumor necrosis factor 
TZ 
 
Transitional zone 
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1. Summary 
Benign prostatic hyperplasia (BPH) and/or prostate cancer (PC) will affect at least 50% of the 
males once they have reached their fifties. However, despite the range of medical therapies 
available, effective treatment against BPH and PC still currently remains inadequate for some. 
 
The annoying symptoms of BPH are mainly attributed to an enlarged prostate. Therefore, the 
current treatment strategy is to halt the androgen-dependent growth of the prostate and reduce 
its size. Several drugs have been employed with variable success to control prostatic growth. 
However, patients tend to self-medicate over a long period. As a result, this leads to another 
problem, unpleasant long-term side effects. 
 
The treatment of PC in its early stages often warrants disease free survival for about 70-80% of 
the patients. Despite early aggressive therapy, 20% of the cases, unfortunately, experience 
disease progression to a state where the cancer no longer responses to therapy. At the 
moment, well-established medical options for this condition are limited and thus PC is one of the 
leading causes of cancer-associated deaths in western countries.  
 
Evidence has supported the undoubted role of the androgen-signalling pathway in BPH, the pre 
cancerous prostatic hyperplasia and dysplasia that may progress to PC. The reduction of 
androgen-dependent prostatic growth has been the rational endocrine therapy for both BPH and 
PC. However, since the etiology of both diseases is multi-faceted, it is necessary to consider 
other contributing factors to develop more effective medication.  
 
Medicinal plants are considered to be multi-component drugs (they contain numerous 
phytochemicals) and are thought to display a wide range of beneficial effects. They have been 
used therapeutically for centuries. Because of their historical place in medicine, they may have 
a better safety profile than synthetic drugs.  
 
The objective of this thesis is to identify tropical medicinal plants, which could be used to target 
or support treatments for BPH and PC. Twenty herbal plants, with no known to date indications 
for both diseases, were selected. They were fractionated by using different ethanol (EtOH) 
concentrations. The initial screen (Chapter 4) aimed to identify plant extracts with the ability to 
inhibit the proliferation of LNCaP cells, an androgen dependent human prostate cancer cell line. 
All extracts were tested at a concentration of 30 µg/mL. 
                                                                                                                                        Summary 
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Four extracts, Api, (70% EtOH Alpinia oxyphylla extract), Aquil (70% EtOH Aquilaria sinensis 
extract), Astra (aqueous Astragalus membranaceus extract) and P9605 (96% EtOH Piper 
cubeba extract) were selected for further investigations.  
 
Recent research has demonstrated that androgens are not solely responsible for BPH and PC, 
estrogens, defective apoptosis and inflammation are, for example, also involved. An 
experimental test system using several methodological approaches was designed to test the 
above-mentioned extracts. The potential cytotoxicity of the extracts was investigated first to 
ensure that they did not attenuate LNCaP growth by inducing unspecific cell death. The extracts 
were also tested on HepG2 cells, a human hepatocarcinoma cell line, to identity any potential 
induction of liver-toxicity. Anti-androgenic and anti-estrogenic effects were determined by 
observing if the extracts 1) blocked the production of certain androgens and estrogens, 2) the 
steroid hormone receptor activation process, and 3) the actions of these sex hormones. The 
ability to induce apoptosis and the anti-inflammatory properties of the extracts were also tested. 
The methods employed were validated and synthetic controls were used whenever possible 
and compared with literature. 
 
Api reduced the cellular viability of LNCaP and HepG2 cells at 20-30 µg/mL. It was not further 
investigated because the apparent reduced LNCap cell growth was most probably attributed to 
due to its cytotoxicity. The other extracts were non-cytotoxic on both cell lines at 30 µg/mL. 
 
Astra inhibited androgen-dependent growth of LNCaP cells, however it did not show significant 
anti-androgenic, anti-estrogenic and anti-inflammatory properties.  Unfortunately, it is beyond 
the scope of this project to discover its anti-proliferative mode of action. 
 
The results of Aquil and P9605 derived from the test system were more promising. P9605 
inhibited 5α-reductase type II and aromatase, which were involved in synthesising 
dihydrotestosterone (DHT) and estradiol respectively. It also antagonised the effects of DHT by 
several mechanisms. Furthermore, it inhibited the cyclo-oxygenases (COX) and 5-lipo-
oxygenase which are involved in generating inflammatory mediators. Aquil possessed similar 
properties as P9605, except that it had no effects on the COXs. 
 
In conclusion, we have identified some possible mechanisms of 2 tropical plants, Aquilaria 
sinensis and Piper cubeba, which could potentially be used to prevent/alleviate BPH and/or PC. 
This is the first time that these plants have shown to possess anti-androgenic and anti-
estrogenic properties. 
                                                                                                                                   Introduction 
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2. Introduction 
2.1 General 
 
Hormone imbalance associated diseases can orginate purely as a disorder of a gland or as a 
consequent of changing hormonal status of an organ due to factors such as age and 
environmental influences. Diseases, which fall into this category, range from mild cases of 
thyroid problems to life threatening illness such as diabetes. In this thesis, the focus will be on 
benign prostate hyperplasia (BPH) and prostate cancer (PC). The etiology of both pathologies is 
not well defined, however it is irrefutable that variations in the hormonal status of the prostate is 
involved. 
 
Both of these dieases are extremely common in aging males; almost 90% of the men develop 
either BPH or PC between their fourth and ninth decades of life. Despite their high prevalence, 
current medical care is unable to eradicate or completely cure BPH and PC, at least for a 
subset of patients. With the unprecedented ageing poulation, there is a demand for more novel 
forms of treatment strategy or perhaps a shift to preventive medicine. 
 
Plants are and hopefully will remain an essential source of therapeutic agents. They are being 
used to isolate bioactive compounds for direct use of drugs (e.g. digoxin, morphine, taxol) and 
for producing bioactive compounds of novel or known structures as lead compounds (e.g. 
metformin and verapamil are based on galegine and khellin respectively) [1]. Furthermore, since 
phytotherapy is becoming more popular amongst patients, plant-based medicine may have 
better patient compliance compared to synthetic drugs. 
 
The search for bioactive components in tropical plants that may offer potential remedy, in one 
way or the other, to BPH and PC will be the centre of interest in this presented work. 
 
The following chapters will provide an overview of the prostate, androgens, androgen receptor, 
BPH and PC. 
                                                                                                                                   Introduction 
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2.2 The prostate  
The human prostate is an androgen regulated exocrine gland surrounding the urethra just below 
the urinary bladder, in front of the rectum. The mature walnut-sized gland consists of branched 
alveolar-ductal structures embedded in a fibromuscular stroma [2]. Although its specific function 
is remains unclear, the prostate produces a clear, slightly alkaline fluid that constitutes 10-30% 
of the seminal fluid volume. 
 
There are 4 distinct zones within the prostate (Table 2.2.1). These zones are derived from 
different embryonic origins, which may therefore explain the occurrence of BPH and PC in 
different areas of the prostate.  
Table 2.2.1 Summary of information regarding the 4 different prostatic zones. 
(From http://en.wikipedia.org/wiki/Prostate) 
The functional unit of the prostate composes of epithelium and stroma components. The 
epithelium consists mainly of secretory columnar epithelial cells, which arranges into a single 
cell layer, lining the epithelium. They synthesize proteins such as prostate specific antigens and 
prostate specific phosphatase and secrete them into the ductal lumen mucin. Notably, majority 
of PC arises from aberrantly functioning secretory epithelial cells. The prostate epithelium also 
composes of basal epithelial cells, neuroendocrine cells, non-epithelial fixed macrophages and 
intra-acinar lymphocytes [3].  
 
The epithelium is physically separated from the stroma by a basement membrane. The 
composition of the stroma includes fibroblasts, smooth muscle cells, endothelial cells, nerve 
cells and infiltrating mast cells and lymphocytes. The prostatic epithelium and stroma interact 
with each other via various hormones and growth factors. The fibroblasts are stimulated by 
androgens to produce and secrete various growth factors such as epidermal growth factor 
(EGF), insulin growth factor (IGF) and keratinocyte growth factor (KGF), which could, in a 
paracrine fashion, induce epithelial cell growth and glandular development [4], [5]. 
Name Proportion Description 
The Peripheral 
Zone (PZ) 
Comprises up to 70% of the total 
glandular mass. 
The sub-capsular portion of the posterior aspect of the 
prostate gland surrounds the distal urethra. This is the 
site where more than 70% of PC originates. 
The Central Zone 
(CZ) 
Constitutes approximately 25% of 
the normal prostate gland. 
This zone surrounds the ejaculatory ducts. It has more 
smooth muscle that the PZ. CZ tumours account for 
more than 25% of all PC. 
The Transition 
Zone (TZ) 
Responsible for 5% of the prostate 
volume. It consists of a pair of 
periurethral glands. 
This zone is very rarely associated with carcinoma. It 
surrounds the proximal urethra and it’s the region of the 
prostate gland responsible for BPH. 
The Anterior 
Fibro-muscular 
zone 
Accounts for approximately 5% of 
the prostatic weight. 
This zone is usually devoid of glandular components 
and composed only of muscle and fibrous tissue. 
                                                                                                                                   Introduction 
 13 
 
The secretory epithelial cells express AR and they require continuous direct androgenic 
stimulation to maintain structural and functional viability. When the androgen level declines 
below a threshold, in the case of surgical or chemical castration, the secretory cells undergo 
apoptosis, causing glandular involution. Animal studies have also indicated that there was a 
∼90% loss of prostatic secretory epithelial cells through apoptosis after physical castration [6]. 
The basal cells remain after castration since most of them do not possess AR. On the other 
hand, a subset of basal cells is speculated to represent stem cells and although they do not 
depend on androgens for survival, they require androgens for proliferation and differentiation 
into secretory cells [7]. 
 
Under normal physiological conditions, these stem cells are stimulated by androgens to 
undergo proliferation and differentiation. Cells with accumulated damage are removed by 
apoptosis and a steady state balance is maintained between cell proliferation and apoptosis. 
However certain pathological assaults may trigger the hyper stimulation of androgen and/or 
growth factors, thus affecting the delicate balance of prostatic cell growth and death. 
Consequently, a subset of epithelial cells may evade the normal checkpoint control of cell cycle 
progression and proliferate aberrantly [3]. 
 
2.3. Hormones in the prostate 
 
Hormones, in particularly the androgens, are essential for the development, growth and 
maintenance of the prostate. Besides androgens, several other hormones and/or their receptors 
have been detected in the prostate. These include estrogen, prolactin and growth hormone. 
Androgen is a term given to any steroid hormone that primarily influences the growth and 
development of the male reproductive system. Although there are other nature androgens 
(Table 2.3.1), testosterone is the primary circulating androgen.  
Table 2.3.1 A list of androgens and their sources.  
(Modified from http://en.wikipedia.org/wiki/Androgen) 
Androgens Source Remarks 
Androstenedione Produced by the testes, 
adrenal cortex, and ovaries 
While androstenediones are converted metabolically 
to testosterone and other androgens, they are also the 
parent structure of estrone. 
Androstenediol Steroid metabolite Is thought to act as the main regulator of gonadotropin 
secretion. 
Androsterone 
By-product of the breakdown 
of androgens, or derived from 
progesterone 
Exerts minor masculinising effects, but with one-
seventh the potency of testosterone. 
Dehydroepiandrosterone 
(DHEA) 
Produced in the adrenal 
cortex from cholesterol A primary precursor of estrogen. 
Dihydrotestosterone 
(DHT) 
Potent metabolite of 
testosterone 
Has 3-10 times greater affinity than testosterone to 
AR. It is synthesized mostly in peripheral tissues, such 
as the prostate. 
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Testosterone is dominantly (>95%) synthesized in the Leydig cells of the testes. Only a small 
fraction of it is synthesised by the adrenal cortex. Testosterone produced is released into the 
bloodstream where a majority is complexed with a "carrier" protein, sex hormone binding 
globulin (SHBG) or albumin. SHBG is produced by the liver and plays an important role in 
regulating the amount of "free" testosterone circulating in the body at any one time.  Only 1-3% 
of testosterone is free to diffuse from the blood stream into the prostatic cells. On the other 
hand, the prostate also possesses enzymes, which are involved in the biosynthesis of 
androgens and even estrogens (Fig. 2.3.2). This indicates that the prostate is capable of 
generating its own supply of sex hormones whenever it deems necessary. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.3.1 Shows some possible intra-prostatic synthesis of androgens and estrogens. 
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2.4. Androgen receptor (AR) 
 
Structure 
The AR is a ligand dependent transcription factor and it belongs to the Type I steroid hormone 
receptors, which is one of the three functionally distinct subfamilies of the nuclear hormone 
gene superfamily. AR was first described in 1969 [8] and cloned in 1988 [9]. The gene is located 
on the X-chromosome at Xq11–12, contains 8 exons, and spans a length of approximately 90 
kb of DNA [10].  
 
Similar to other steroid receptor proteins, the full-length AR contains 4 domains: the amino-
terminus regulatory domain, a highly conserved DNA-binding domain, a hinge region, and the 
ligand-binding domain [11]. Unlike the progesterone and estrogen receptors, the concept that 
another isoform of AR exists is not widely accepted due to lack of substantial evidence [12]. 
 
 
 
Fig. 2.4.1 A structural and functional map of a typical AR. It has approximately 900 amino acids and a molecular 
mass of ∼110kDa. The amino-terminal consists of a constitutively active activation function (AF-1) and a ligand-
dependent activation function (AF-2) arises in the LBD [13]. The DBD has 2 zinc fingers which that dictate the 
specific binding to the ARE. 
 
 
Ligand dependent Activation 
Unliganded ARs are sequestered in the cytoplasm as a multi-protein complex. They are 
associated with immunophilins and heat shock proteins (HSPs) 90, 70, and 56, which stabilize 
their tertiary structure and prevent them from constitutive activation [14]. When bound to a 
ligand, AR is phosphorylated, undergoes a conformation change and dissociates from HSPs. 
The activated AR forms a homodimer with another AR. This consequently exposes a nuclear 
localization signal within the dimer, where importins bind and facilitate the translocation of the 
ligand bound AR to the nucleus [15]. Once within the nucleus, they bind to canonical androgen 
response elements (ARE) on various androgen target genes. This can turn on or off 
transcription of the particular DNA. Co-regulatory proteins (co-activators/co-repressors) are 
recruited to form a mega-protein complex, which is poised to interact with other transcriptional 
mediators, cofactors and basal transcriptional machinery to modulate target gene transcription 
[11]. 
 
Amino-terminal  
Transactivation function 
(Exon 1) 
DNA binding 
domain (DBD) 
(Exons 2-3) 
 
Hinge 
(Exon 4) 
 
Ligand Binding 
domain (LBD) 
(Exons 5-8) 
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Ligand independent activation 
Nuclear receptors are regulated by reversible phosphorylation and thus may also be activated 
by signalling pathways that originated at the cell surface. AR possesses a consensus 
phosphorylation site which indicates that it could be a substrate for protein kinase A & C (PKA & 
PKC), mitogen activated kinase and casein kinase II. This hypothesis is supported by the 
observation that PKA and PKC could enhance AR transactivation [16]. A number of other AR 
associated proteins (ARA) such as ARA 54, 55 and 70 also enhances AR transactivation. 
 
Effects of AR activation 
Testosterone and DHT bind with different affinities to the AR. This difference in binding affinity 
results in different levels of AR activation and therefore distinctive effects [17] (Table 2.4.1). 
Androgens modulate the synthesis of growth factors (GF) and their receptor availability.  
Table 2.4.1 The different effects of androgens mediated by AR. 
Effects of Testosterone Effects of DHT 
• Development of the internal accessory sexual organs 
• Regulation of FSH synthesis 
• Regulation of GF receptors 
• Maintenance of epithelium, microvilli, golgi secretory 
activity 
 
 
 
• Development of the external sex organs 
• Increase DNA replication, cell growth 
• Induce SHBG and PSA production 
• Induce mesenchymal cells to secrete KGF and 
FGF 
• Downregulates TGF-β 
• Increasing angiogenesis due to upregulation of 
EGF and vascular endothelial growth factor 
• Inhibits apoptosis in LNCaP cells [18]. 
• Antiproliferative and PSA induction effects of 1α-
25-dihydroxyvitamin D3 on LNCaP are DHT 
dependent [19]. 
One possible explanation to account for these differences is that testosterone dissociates 3 times faster than DHT 
and is less effective in stabilizing the AR. The differences in dissociation rate of the two ligands to AR could be 
directly related to their different abilities in stimulating androgen responsive genes [17]. 
 
Degradation 
Steroid hormone receptors have relatively short half-lives and they undergo systematic protein 
degradation. This is important in regulating the amount and duration of steroid receptor ligand 
effect. A study using green fluorescent protein technology demonstrated that AR migrated to the 
sub-nuclear compartment in the presence of the androgen within 15-60 mins. AR migrated 
rapidly back to the cytoplasm upon ligand dissociation and maintained its ability to re-enter the 
nucleus for at least four rounds of AR recycling after initial androgen treatment before 
degradation [20]. AR may be degraded by two independent pathways, Akt-proteasome and 
phosphatase and tensin homolog (PTEN) caspase-3 pathways [12]. 
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Regulation 
AR expression is regulated at several levels: AR mRNA translation, transcription, post-
transcription, protein, half-life and degradation (Table 2.4.2). AR is the main instrumental tool in 
eliciting the effects of androgens. However androgens, in turn, play an immense role in 
regulating the action and levels of AR. 
 
Table 2.4.2: Briefly describes the different possibilities to regulate the levels of AR 
Levels Regulation mode 
AR mRNA transcription Androgens: Results are controversial. Androgens decrease AR mRNA LNCaP cells 
and in rat ventral prostate [21], [22]. However other groups have shown an up-
regulation of AR mRNA in rat and mouse prostate [23], genital skin fibroblasts [24]. 
FSH: Increases AR mRNA in Sertoli cells. 
Growth hormone, Prolactin, and EGF: Increase AR mRNA in prostatic cells. 
AR protein expression Androgens: Reported to modulate both stability and translation efficiency of AR mRNA 
[25]. 
AR nuclear import Androgens: AR transfer is more efficient when bound to DHT then anti-androgens. 
AR protein degradation Androgens: Half-life of AR in LNCaP cells is ∼ 3 hours but it longer than 10 hours in 
the presence of 10 nM of DHT [26]. 
 
2.5. Benign Prostatic Hyperplasia (BPH) and Prostate cancer (PC) 
2.5.1. Introduction 
BPH  
BPH could be defined  
1) Histologically: the microscopic benign proliferation of the prostatic stroma and epithelium in 
the transitional zone [27].  
2) Clinically: the palpable enlargement of the prostate, which can be detected by digital rectal 
examination or ultrasonographic examination [27]. 
 
Microscopic nodular hyperplasia increases linearly with age in all ethnic groups and BPH is 
clinically identifiable in at least 50% of men over 50. However, only about 30% to 50% of the 
cases with clinical gland enlargement manifest lower urinary tract symptoms (LUTS) [28]. LUTS 
is a collection of annoying urinary symptoms associated with prostatic hyperplasia, which 
include urinary hesitancy, urinary retention and increased risk of urinary tract infections.  
 
Functionally, the prostate reaches maturity at puberty. After achieving adult size, the prostate 
remains essentially the same size for several decades. Then, in midlife and beyond, prostatic 
growth occurs again in majority of the men. The explanation for this reawakening of the 
prostatic cells is still unclear [2].  
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A study done in 2004 identified certain risk factors for BPH and results have shown than Asian 
Americans have the lowest risk of clinical BPH. Alcohol and possibly cigarettes are related to a 
lower risk for BPH [29]. Other epidemiological studies have indicated that several risk factors 
associated with cardiovascular diseases apply for BPH as well. These include obesity, 
hypertension and diabetes type II [30], [31].  
 
Introduction: PC 
PC develops when prostate cells mutate and begin to multiply uncontrollably. 1 out of 6 men are 
now being diagnosed with PC [32].  Although in most cases, they are not clinically relevant, PC 
could be fatal for a proportion of the men. The current problem/challenge is to distinguish the 
nature of PC a man may have at a given time; 
• Microscopic cancer that will never cause a problem. 
• A clinically relevant cancer that will cause mortality if left untreated. 
• Cancer that has already metastasized to distant organs hence incurable with localized 
therapy. 
 
PC that metastasizes to other parts of the body, especially to the bones and lymph nodes, 
occurs in 2 general stages; androgen sensitive (AS) and androgen independent (AI). The initial 
PC usually arises from androgen-dependent epithelium, which requires androgens to grow, and 
is sensitive to androgen deprivation treatment (ADT). However, after prolonged ADT, the 
tumour progresses to an AI state where it no longer responses to ADT. It must be noted that 
although AI PC does not respond to ADT, androgens are still detected in these AI cancers [32]. 
 
2.5.2. Role of androgen/AR signalling pathway  
 
Role of androgen axis in BPH 
DHT stimulates glandular epithelium growth in the prostate and it is the major cause of rapid 
prostate enlargement that occurs between puberty and young adulthood. A study in 1974 
observed that men deficient in 5α-reductase had hypoplastic prostates [33] and the relative 
success of Finasteride, a 5α-reductase type II blocker, in retarding prostatic growth by reducing 
DHT production both substantiate the role of DHT in BPH. It is well documented that as men 
age, their testosterone levels decline. Some researches have indicated that despite an overall 
decline in testosterone levels, the prostate is still able to synthesise similar quantities of DHT. It 
is therefore hypothesized that the changes in the equilibrium between testosterone and DHT 
may lead to an increase in prostatic growth [2]. 
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Role of androgen axis in PC 
Since the prostate is an androgen-dependent organ, it is rational to presume that prostate 
malignancy develops under abnormal androgen signalling. This hypothesis is, to some extent, 
supported by observations that eunuchs do not develop PC and that a higher incidence of PC is 
found in men who used androgens as anabolic agents or therapeutics [34].  
 
Although patients show positive response initially to ADT, continuous treatment often results in 
PC progressing to AI states within 18-24 months [35]. There are several postulated theories 
explaining this development of resistance. Some of which, involve the AR or the development of 
alternative signalling pathways that bypass the function of AR [36].  
 
Somatic Mutations of AR often bestow the receptor with hypersensitivity and promiscuous 
usage of ligands. The mutated receptor could be trans-activated by lower concentrations of 
androgens, by anti-androgens, and by non-androgenic ligands [37], [38]. About 50% of the 
mutations reported in ligand binding domain have been found to be associated with AI PC. 
T887A substitution in AR, which is found in LNCaP cells, allows it to be activated by other 
steroids and even by anti-androgens [39]. In addition, the R726L AR mutant is known to be 
activated by estradiol. PC may consist of clones with a range of different types of AR mutations 
[40].  
 
AR amplification is rarely found in AS cancer but is common in recurrent therapy-resistant 
cancer [41], [42].  
 
Ligand-independent activation of AR by growth factors such as IGF-I, KGF, EGF [43], and by 
cellular signalling regulators such as butyrate, interleukin-6 (IL-6), bombesin, and activators of 
the PKA signalling pathways are capable of transactivating AR [44]. 
 
Altered regulation or mutation of co-regulators is a potential mechanism for altered PC 
growth. Besides AR-specific co-regulators, more general steroid receptor co-regulators such as 
CBP, SRC-1, ARA70, and TRAM-1 as well as oncogenic molecules such as BRCA-1, RB, and 
Her2/neu have been demonstrated to influence AR trans-activation [45].  
 
The progression of PC is likely to be the result of an abnormal AR status. Prolong ADT may 
contribute to the progression to an AI state by exerting selective pressure for clones expressing 
different AR phenotypes thus modifying the AR status of the tumour. In summary, the androgen 
axis is involved in both development of PC and the progression of the cancer to AI state. 
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Fig. 2.5.2.1 Possible pathways leading to AI PC. (Taken from [46]). 
 
1) In the outlaw pathway, receptor tyrosine kinases (RTKs) are activated, and the AR is phosphorylated by 
either the AKT (protein kinase B) or the mitogen-activated protein kinase (MAPK) pathway, producing a 
ligand-independent AR.  
 
2) In the promiscuous pathway, the specificity of the AR is broadened so that non-androgenic steroid 
molecules normally present in the circulation can activate it. 
 
 
3) In the hypersensitive pathway, more AR is produced (usually by gene amplification), AR has enhanced 
sensitivity to compensate for low levels of androgen, or more testosterone is converted to the more potent 
androgen, dihydrotestosterone (DHT), by 5α reductase. 
 
4) In the bypass pathway, parallel survival pathways, such as that involving the anti-apoptotic protein BCL-2 
(B-cell lymphoma 2), obviate the need for AR or its ligand. 
 
 
5) In the stem-cell repopulation pathway, androgen-independent cancers stem cells are resistant to therapy 
and eventually become the primary population within the tumour. 
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2.5.3. Role of estrogen/ER signalling pathway 
 
Role of estrogen axis in BPH 
As men age, the intraprostatic estradiol concentration increases or remains constant while the 
androgen concentration decreases. There is a strong correlation between the increasing 
estradiol:DHT ratio and stromal hypertrophy [47]. Takase et al. have detected estrogen 
receptors and enzymes involved in estrogen metabolism in human prostates [48]. Although the 
role and mechanism of estrogens in the prostate is still unclear, there is growing evidence that 
estrogen could modify prostate growth and differentiation. An estrogen dominant environment is 
speculated to increase the production of androgen receptors and thus encouraging prostatic 
growth by sensitizing the prostate to androgen [49]. The current hypothesis is that the prostate 
locally produces estrogens to modulate the activity of epithelial and stromal cells. 
 
Role of estrogen axis in PC 
Evidence that estrogens are involved in the genesis and progression of prostate cancer came 
mainly from experiments with organ cultures of normal rat, human prostate or human prostate 
cancer samples. In these studies, estrogens were found to stimulate DNA synthesis and induce 
metaplastic epithelial morphology in both human [50] and rat prostate [51]. High doses of 
testosterone given together with estradiol, but not alone, stimulated carcinogenesis in adult 
male rats [52]. Aromatase knockout mice, which are estrogen deficient, did not develop PC [53]. 
Epidemiological data also showed that men with high serum levels of estrogens have a greater 
risk of PC [54], [55].  
 
On the other hand, the putative beneficial effects of dietary estrogens are evident from 
laboratory and clinical studies. Dietary estrogens, which include phytoestrogens, lignans and 
flavonoids, have been promoted to reduce and prevent prostate diseases [56], [57]. 
Epidemiological studies have suggested a link between increased consumption of phyto-
estrogens to a lower incidence of PC. This is particularly true when comparing men living in 
Asia with men in the West, where dietary estrogens intake is lower and PC incidence is higher 
[58]. 
 
These conflicting data indicate the diverse roles of estrogens. These differing actions of 
estrogens are mediated by two estrogen receptor (ER) subtypes; ER-α and ER-β. ER-α is 
associated with aberrant proliferation, inflammation and the development of malignancy, 
whereas ER-β is associated with anti-proliferation, differentiation and apoptosis [59].  
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Estrogens induce proliferation as mentioned earlier and the multi-layering of the prostatic 
epithelial cells. Squamous metaplasia (SQM), the proliferation stimulated by estrogens, is 
aberrant in contrast with the ordered and coordinated proliferation induced by androgens. This 
response is observed only in ER-β knockout (KO) mice and not ER-α KO mice by Risbridger et 
al. They could also demonstrate, using tissue recombination techniques, that stromal and 
epithelial ER-α expression is a prerequisite for the development of SQM [59], [60]. This aberrant 
proliferation may progress and lead to PC if left uncontrolled. 
 
2.5.4. Role of apoptosis 
 
The interactions of androgens with the prostate epithelium, stroma, other hormones and growth 
factors (GF) form a complex system, which regulates prostate growth. In normal tissues, 
homeostasis is maintained by a balance between cell proliferation and apoptosis. Apoptosis, 
also known as programmed cell death, is a regulated process, consisting of a series of 
molecular events that lead to cell death. 
 
BPH may result from an over-activity of cell proliferative processes induced by hormones or 
from a reduced rate of apoptosis. For example, the changes in the balance between different 
hormones may up or down regulate growth factors or other proteins, which are involved in 
inducing apoptosis, thus leading to an overall increase in cellular growth. 
 
Apoptosis is one of the most potent defences against cancer because it eliminates deleterious 
cells. Therefore, the pathogenesis of cancer is closely related with aberrantly regulated 
programmed cell death. The resistance to apoptotic cell death in response to radiation and 
chemotherapy is another property of recurrent prostate tumour cells besides androgen 
independence. Bcl-2 is an anti-apoptotic protein, and its over expression has been associated 
with resistance to androgen deprivation and poor outcome in some prostate cancer patients 
treated with radiotherapy [61]. Furthermore, Zhou et al have recently shown that prostatic 
epithelium-specific deficiency for p53 and Rb tumour suppressors, which are pro-apoptotic 
proteins, leads to metastatic cancer in mice [62]. One approach to combat PC would be to 
target some of these specific apoptotic regulators. 
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2.5.5. Role of inflammation 
 
Role of inflammation in BPH 
Prostatic inflammation is very common in BPH patients. Histological studies of BPH tissues 
have detected inflammatory cell infiltrates of varying densities in 30%- 50% of the cases [63].  
Inflammatory infiltrate such as macrophages and lymphocytes are known to produce growth 
factors such as bFGF, cytokines IL-1 and IL-6. In situ studies have indicated that there is an 
elevated expression of pro-inflammatory cytokines in BPH. It is speculated that IL-6, IL-8, IL-17 
may perpetuate chronic immune response and induce fibromuscular growth by an autocrine or 
paracrine loop or via induction of cyclo-oxygenase 2 (COX-2) expression [64]. COX-2 is a major 
enzyme that converts arachidonic acid to prostaglandins. Prostaglandins have various roles in 
mediating and moderating inflammation and are associated with the progression of BPH [64].  
 
Moreover, aromatase gene (CYP19) is regulated by a promoter (PII), which is responsive to 
inflammatory cytokines [65]. An increase in aromatase expression increases local estrogen 
levels that may lead to an increase in prostatic proliferation. 
 
A recent study has indicated that consumption of non-steroidal anti-inflammatory drugs 
(NSAIDs) is linked with lower risk of developing BPH and LUTS [66]. It is unclear if inflammation 
is the cause or result of BPH but its involvement indicates that anti-inflammatory drugs may help 
to retard development and worsening of the disease. 
 
Role of inflammation in PC 
There is much evidence that chronic inflammation leads to an increased cancer risk. 
Eicosanoids, generated by the cyclo-oxygenases (COXs) and lipoxygenases (LOXs), are 
believed to play important roles in tumour promotion, progression and metastasis besides being 
inflammatory mediators. Matsuyama et al have observed that while 5 and 12-LOX were present 
in low amounts in BPH and normal prostate tissues, marked increase in 5 and 12-LOX 
expressions were found in prostatic intraepithelial neoplasia (PIN) and PC tissues. Furthermore 
they also saw that LOX inhibitors could reduce the growth of PC cell lines via apoptosis dose 
dependently [67]. In addition, recent epidemiologic studies have suggested that the use of 
NSAIDs may also be associated with a reduced risk of prostate cancer. A large cohort study 
was done in 2005 to investigate aspirin and other NSAIDs and PC incidence. It was concluded 
that long term NSAID usage modestly reduced the risk of prostate cancer [68]. Thus targeting 
certain aspects of the inflammatory pathway may be another approach to treat PC. 
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2.6. Current Treatments 
 
Current treatments in BPH 
Many men with BPH are asymptomatic and many others are not bothered by their symptoms. 
Therefore watchful waiting is an appropriate management for these patients. When symptoms 
affect quality of life, the main objectives would be to provide fast and sustained relief of the 
symptoms and to control disease progression. 
 
Conventional pharmacological options include α1-blockers, 5α-reductase inhibitors, or for men 
with larger prostates, a combination of the two (Table 2.6.1). Alternative medicine, which 
includes phytotherapeuticals, is also very popular amongst BPH patients (Table 2.6.2). Surgical 
intervention was the golden standard treatment for several years. However, the incidence of 
after-surgery complications such as incontinence, impotence, urinary tract infections and the 
need for re-intervention is clinically significant. Moreover, most patients have been reported to 
prefer a less aggressive intervention.  
 
Current treatments in PC 
Although there are several PC treatments (e.g. prostatectomy, radiation therapy, watchful 
waiting, chemotherapy), androgen deprivation therapy (ADT) has been the cornerstone of 
therapy ever since its efficacy for treating prostate cancer was first demonstrated by Huggins 
and Hodges in the 1940s. The main strategy of ADT is to decrease the production or block the 
actions of testosterone on prostatic cells. ADT cannot eradicate PC but only slows down the 
cancer’s growth and reduces the size of the tumour(s). 
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Table 2.6.1 Current prescribed pharmaceutical drugs for BPH.  
 
 
Drug Class Mechanisms Primary effects Examples Side effects 
α-adrenergic receptor 
blocker 
Antagonises the α- adrenergic 
receptors, which cause the 
contraction of smooth muscles in 
the prostate and bladder.  
Relaxes the bladder 
and prostate muscles, 
thus relieving the 
symptoms of BPH 
(difficulty in urination). 
Terazosin, 
Doxazosin, 
Alfuzosin 
fatigue, 
back pain, headache, 
weight gain, 
decreased sexual ability, 
blurred vision, 
oedema, 
rhinitis, 
upper respiratory tract infection, 
orthostatic hypotension 
α1A-adrenergic receptor 
blocker 
More selective for α1A-
adrenergic receptor which are 
the dominant α-adrenoceptors in 
the prostate.  
More specific for 
symptomatic treatment 
of BPH. 
Tamsulosin abnormal ejaculation,  
back pain, chest pain,  
diarrhoea,  
sinus problems,  
sleepiness 
5α-reductase Type II 
inhibitor 
Specific inhibition of the 
conversion of testosterone into 
DHT by 5α-reductase Type II, 
the main isoform in the prostate. 
Halts the growth of the 
prostate. 
Finasteride Impotence, 
allergy to active ingredients (hypersensitivity), 
rash (allergic reaction), 
breast tenderness/swelling, 
ejaculation disorders, 
decreased sex drive 
5α-reductase Type I & 
II inhibitor 
General inhibition of the 
conversion of testosterone into 
DHT by targeting both isoforms 
of 5α-reductase. 
Halts the growth of the 
prostate. 
Dutasteride similar to finasteride 
Muscarinic antagonist Inhibits M2 and M3 receptors 
which have roles in the control of 
urinary bladder function. 
Relieves urinary 
difficulties, including 
frequent urination and 
inability to control 
urination. 
Tolterodine dry mouth, 
blurred vision, 
upset stomach, 
headache, 
constipation, 
dry eyes, 
dizziness 
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Table 2.6.2 List of popular phytotherapy used by BPH patients. 
 
 
 
Plant Mechanisms Active compounds Results from literature 
Serenoa serrulata 
Saw Palmetto 
(Permixon) 
Inhibits 5α-reductase I&II  
Anti-proliferative effects  
Anti-inflammatory  
Apoptotic effects  
Inhibits aromatase 
Anti-androgenic 
Anti-estrogenic [64] 
 
Sterols (β-sitosterol, 
campesterol, stigasterol) and 
flavonoids 
• Serenoa serrulata extract inhibited >70% of the 
activities of 5α reductase I &II with 10 µg/mL [69]. 
• Inhibited aromatase with IC50 of 100 µg/mL [47]. 
• 100 µg/mL of the extract inhibited thymidine 
incorporation in LNCaP and PC-3 cell lines by more 
than 50% [70]. 
Pygeum africanum  
African plum tree 
(Tadenan) 
Prevents proliferation induced by 
PKC, bFGF, EGF, IGF of rat 
prostatic fibroblasts. 
Mild anti-inflammatory effects 
Antiandrogenic activity  
  
Sterols, acidic phenols, 
triterpenoids 
 
• 600 µg/mL of P. africanum extract inhibited androgen 
action by 40-60 fold [71]]. 
• Inhibited thymidine incorporation in LNCaP and PC-3 
cell lines with an IC50 of 2.5 µg/mL [72]. 
Urtica dioica  
Nettle root  
 
Inhibits aromatase 
Inhibits leukocytes 
Immuno-modulatory 
Anti-proliferative effects 
 
Sterols, triterpenic acids, 
lignans, phenols 
• Ethanolic extracts inhibited aromatase activity with 
IC50 of >100 µg/mL [47]. 
Epilobolium 
Willow herb 
 
Anti-inflammatory 
Anti-androgenic 
Anti-proliferative effects [69] 
Sterols, triterpenes, flavonoid 
glycosides. 
• 75-100 µg/mL of Epilobolium rosmarinifolium extract 
inhibited thymidine incorporation in PZ-HPV-7 cell line 
[69]. 
• Epilobolium parviflorum extract inhibited 5α-R with IC50 
of 160 µg/mL [73].  
Vitex agnus  
Chaste tree 
 
Reduces prolactin levels [71] 
Antiproliferative effects 
Apoptotic effects [72] 
Flavonoids, iridoid glycosides, 
and terpenoids 
• 10-30 µg/mL of Vitex agnus-castus fruit extracts 
inhibited proliferation of prostate cancer cell lines by 
50% however at these concentrations there was an 
increase in cytotoxic effect by 2 folds compared to 
solvent controls [74].  
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Table 2.6.3 A list of common PC therapies that involve changing the hormonal status in the body. 
Treatment Mechanisms Effects Examples Side effects 
Orchiectomy  
 
Surgical removal of 
testes.  
Reduce androgen production.  Disfiguring, impotency, hot flashes. Side effects are 
permanent. 
LHRH agonists and 
antagonists  
Desensitize the 
pituitary to native 
GnRH stimulation. 
Reduce androgen production. 
 
Agonist: 
Zoladex, Lupron 
Antagonist: 
Abarelix 
Impotency, hot flashes, altered lipid levels, decreased 
muscle strength 
GnRH agonists cause testosterone surge and flare 
initially 
Anti-androgens  Bind to HSPs and 
prevent androgens 
from binding to AR.  
Block actions of androgens. Casodex, 
flutamide, 
nilandron 
Gynecomastia (breast enlargement) 
5α-reductase 
inhibitors 
Block the 
conversion of 
testosterone to a 
more potent form, 
DHT. 
Reduce DHT production. Finasteride Prostate cancer prevention trial have shown that 
although men taking finasteride had fewer prostate 
cancers overall (18 % of men in the finasteride group 
developed prostate cancer vs. 24% of men in the 
placebo group), the cancers in the finasteride group 
were of a higher grade (37% of cancers in the 
finasteride group were high-grade vs. 22% of the 
cancers in the placebo group). High-grade prostate 
cancers may be more aggressive and are more likely 
to spread outside the prostate. 
(http://www.cancer.gov/cancertopics/factsheet/pcptqa) 
Combined anti-
androgen blockade 
(CAB) 
Therapy with an 
LHRH agonist and 
an anti-androgen. 
Reduces androgen production and 
block androgen actions. Reduces 
testosterone surge and flare, 6 months 
survival advantage [75]. 
 
Small clinical benefit. Liver toxicity and additional cost 
may outbalance the benefit 
Long term CAB leads to sexual dysfunction, facial hair 
loss, muscle loss, osteoporosis and gynecomastia. 
Intermittent 
Androgen blockade 
 Tumour cells surviving withdrawal are 
forced into normal pathways of 
differentiation by androgen 
replacement, apoptotic potential may 
be restored and disease progression 
may be delayed. Less toxicity and 
improved quality of life [75]. 
 Difficult to decide when and how treatment should be 
carried out. 
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2.7. Inadequacy in present drug treatments and ongoing research. 
 
Inadequacy in present in BPH treatments 
At present, the two main pharmaceutical drugs prescribed by doctors are 1) finasteride to shrink 
the prostate and 2) α-blockers to relax smooth muscle tone. Both medications have enjoyed 
relative success with a large proportion of patients in relieving the disturbing LUTS symptoms. 
However, long-term application of these drugs leads to unpleasant side effects. Furthermore 
there are patients whose conditions were not improved by both 5α-reductase inhibitor and α-
blockers. Currently, there is a lack of preventive medication for asymptomatic BPH against the 
possible enlargement of the prostate and LUTS development. 
 
On going research for new BPH treatments 
Besides conventional medicine, there are some popular alternative plant-based drugs. The 
most widely used herbal remedy in the United States and Europe is Saw palmetto. It is reported 
having actions similar to finasteride but with no major side effects. In 2006, a double blind, 
placebo-controlled, randomized clinical trial conducted by Bent et al, concluded that Saw 
palmetto did not improve symptoms or objective measures of BPH [76]. However, it must be 
pointed out that a specific preparation of Saw palmetto was tested. 
 
To date, the other herbal remedies mentioned in table 2.6.2 have not undergone such rigorous 
clinical trials. Some interesting potential compounds against BPH, which are currently under 
investigation, include  
• Extracts from the fruits from Brahea aramata [77] and Cuban royal palm [15], which also 
belong to the same Arecaceae family as Saw Palmetto. 
• Lycopene, the primary carotenoid in tomatoes [15], [78]. 
• Silymarin, polyphenolic flavonoid from Silybum marianum [79]. 
• Indole-3-carbinol, a naturally occurring compound found in vegetables of the Brassica 
genus [80], [81]. 
• Isoflavones from Soya extracts [82]. 
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Inadequacy in present in PC treatments 
Reduction of androgen-dependent prostate growth is still the rational endocrine therapy for AS 
PC. Unfortunately, ADT is detrimental in the long run. When the disease has progressed to an 
AI status, well-established treatment options are limited.  
 
On going research for new PC treatments 
The current research includes 
• Anti-angiogenesis therapy: Drugs to stop tumours from making new blood vessels, thus 
inhibiting their growth. The first anti-angiogenic drug, Bevacizumab (Avastin), approved 
by the FDA in 2004, blocks vascular endothelial growth factor receptor [32].  
• Chemotherapy therapy: Docetaxel (Taxotere), which is an anti-mitotic drug, has shown 
to prolong the life span of PC patients [32], [46].  
• Satraplatin: a platinum analogue that is being looked at for AI PC. 
• Combination therapy: Compounds that enhance the effects of current drugs. Calcitrol, a 
vitamin D derivative, have shown promising result when combined with docetaxel. 
• Vaccines: APC8015 (Provenge) uses autologous antigen presenting cells (APCs) 
loaded with the recombinant fusion of prostatic acid phosphatase linked to a molecule 
that specifically targets a receptor expressed on the surface of APCs. This approach 
aims to stimulate the body to develop an immune response to PC cells. Onyvax-P is 
another vaccine made from a cocktail of 3 irradiated allogeneic cell lines. Each cell line 
expresses antigens that represent a different stage of PC, therefore Onyvax-P contains 
a broad range of known and yet to be identified cancer-specific antigens [46]. 
• Radiolabeled monoclonal antibodies: Radiolabeled antibodies targeting prostate specific 
membrane antigens (PSMA) conjugated with various radiopharmaceuticals (e.g. 
lutetium) are being developed. PSMA is highly expressed in all PCs and on the tumour 
vascular endothelium of virtually all solid carcinomas but not on normal vascular 
endothelium. Therefore it may be possible to specifically kill PC tumour cells without 
harming normal cells [46]. 
• Targeting several intracellular cell-signalling pathways involved in cell growth such as 
MAPK pathway, raf proteins and mammalian target of rapamycin (mTOR) and receptors 
of growth factors (e.g. EGF, IGF)  [32], [46]. 
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2.8. Discussion 
 
Although BPH and PC are inherently different pathologies, they share similar aetiology and 
certain treatments may be applied for both. Clearly BPH, in comparison to PC, could be 
controlled with more ease. The treatment strategy for BPH depends on the stage of the disease. 
 
• Asymptomatic: Prevention against possible prostatic enlargement may be achieved 
through changing dietary habits. There are several compounds (e.g. lycopenes, 
isoflavones) in fruits and vegetables that may control prostate growth.  
• Symptomatic: Besides the 2 main pharmacological approaches to BPH: α1-blockers and 
5α-reductase inhibitors, new medicine should also be developed to target other areas 
such as inflammation and the estrogen signalling pathways. 
 
Now that we have a greater understanding of the molecular events involved in PC, the view that 
ADT is an effective therapy was simplistic. PC requires more individualized treatment and a 
systematic approach to target not only the cancer cells but also the microenvironment in which 
they proliferate. There are several novel approaches to tackle PC, especially AIPC (e.g. 
vaccines, antibodies, genetic therapy and inhibition of GFs). This project focuses on using 
plants that may offer some help against PC (prevention and treatment) by developing phyto-
compounds that are cytostatic, downregulate AR levels, induce apoptosis and reduce 
inflammation. 
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3. Aim of the thesis 
 
The purpose of this project is to identify tropical plants with bioactive profiles that could be used 
to potentially prevent and/or provide additional supportive treatment for BPH and PC.  
 
A bio-active profile of a plant extract should include properties that  
• reduce proliferation induced by androgens and estrogens, 
• possess apoptotic abilities to counter over proliferation,  
• have anti-inflammatory effects, 
• down regulate androgen receptors, 
• are non cytotoxic 
 
The present work involves screening several plant extracts for potential anti-proliferative effects 
on the human prostate cancer cell line, LNCaP. Potential candidates will then be further 
investigated to determine their mode of actions in reducing the cellular growth according to the 
flowchart below. 
 
 
Fig. 3.1 Flowchart of the experimental setup, which would be implemented for the further investigation of plant 
extracts. 
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4. Primary screen 
4.1 Introduction 
There are several approaches to select plants as potential candidates;  
1) Random selection followed by chemical screening and biological assays 
2) Follow up of ethno-medical usage of plants. 
 
Since this project is geared towards tropical plants, 20 plants from different Asian countries 
were selected (Table 4.1.1) for investigation based on their uses in various traditional medical 
systems.  
 
The choice of solvents is unlimited. For this project, we have decided to use water, 30% (w/w), 
and 70% (w/w) ethanol (EtOH) for the initial extraction. Using different concentrations of 
ethanol, different groups of phytochemicals will be extracted depending on their polarity. For 
example, samples extracted with 70% EtOH will contain more lipophilic components than the 
aqueous extracts. The extracts, at 30µg/mL, were then tested for their potential antiproliferative 
effect on LNCaP cells. 
 
Table 4.1.1 List of plants selected for the screen. 
Plant Family Abbreviation Part of Plant 
Alpinia oxyphylla Miq. Zingiberaceae Alp Fruit 
Aquilaria sinensis Gilg. Thymelaeaceae Aquil Heartwood 
Astragalus membranaceus Fisch. Leguminosae Astra Root 
Curcuma aeruginosa Roxb. Zingiberaceae Curum Rhizome 
Epilobium parviflorum Schreber Onagraceae Epi Leaves 
Eucommia ulmoides Oliv. Eucommiaceae Euco Bark 
Fritillaria thunbergii Miq. Liliaceae Frit Bulb 
Gleditsia sinensis Lam. Leguminosae Glet Spines 
Kochia scoparia L. Chenopodiacae Kosco Fruit 
Leonurus japonicus Houtt. Labiatae Leon Whole 
Lindera aggregate Kosterm Lauraceae Lind Root 
Oldenlandia diffusa Roxb. Rubiaceae Old Leaves 
Patrinia scabiosaefolia Fisch. Valerianaceae Pat Whole 
Piper cubeba L. Piperaceae Piper Fruit 
Pueraria mirifica Airy Shaw & Suvat Fabaceae Pueraria Tuber 
Rubus chingii Hu Rosaceae Rubi Fruit 
Schisandra chinensis Baill. Schisandraceae SchChi Fruit 
Schisandra sphenanthera Rehder & E. 
Wilson  Schisandraceae SchSph Fruit 
Sparganium stoloniferum Buch- Ham. Sparganiaceae Sparg Rhizoma 
Trichosanthes kirilowii Maxim. Cucurbitaceae Tricho Root 
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4.2 Materials and methods 
 
Materials 
Fetal bovine serum (FBS) and the other reagents are of the highest quality available and were 
purchased from Sigma (Buchs, Switzerland) if not otherwise stated. 
 
Preparation of the extracts 
The dried plant materials were milled and extracted with 3 solvents; ultra pure water, 30% EtOH 
(w/w) and 70% EtOH (w/w). The mixtures were left overnight and the liquid fraction was 
separated from the solid residue by filtering through an AF-6 filter paper first, then through a 4-7 
µm filter paper (Scleicher & Schuell, Dassel, Germany). The dried mass content of each liquid 
extract was then determined.    
 
Cell culture 
Human prostate adenocarcinoma cell line LNCaP-FGC was obtained from the American Type 
Culture Collection (Manassas, VA, USA). LNCaP cells were cultured with 1640 medium 
containing 2 mM L-glutamine and 10 mM HEPES, 1 mM sodium pyruvate, 2.5 g/L glucose, 3.5 
g/L sodium bicarbonate and supplemented with 10% FBS. The cells were kept in a humidified 
incubator at 37°C and 5% CO2 and passaged at 70-80% confluency.  
 
Proliferation assay using WST 
LNCaP cells were seeded at 5000 cells/well in 96-well plates. After 24 hours of pre-incubation, 
they were treated with 30 µg/mL of the extracts for 4-6 days. To detect changes in cellular 
numbers, WST-1 (Biovision, Mountain View, CA, USA) was added and incubated for 90 mins. 
This assay measures the ability of mitochondrial dehydrogenases in living cells to cleave 
tetrazolium salt WST-1 to formazan. The absorbance of the yellow formazan dye produced by 
viable cells was measured at 450nm with TECAN infinite 200 multifunctional microplate reader 
(Tecan Männedorf, Switzerland). The amount of formazan dye produced indicates the 
proportion of viable cells with respect to the solvent control (1% EtOH). However, it should be 
noted that it is assumed that the extracts do not directly interfere with the mitochondrial activity. 
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4.3 Results and Discussion 
 
Results of screen 
Twenty plants were screened for their potential antiproliferative effects on LNCaP cells. For 
each plant, 3 solvents, water, 30% EtOH and 70% EtOH were used to prepare the extracts. 
Extracts that could reduce the cell numbers by 50% in comparison to the solvent control were 
considered for selection. 
 
Out of the 60 extracts, water extracts of Alpinia oxyphylla and Astragalus membranaceus 
(Fig.4.1A) and Alpinia oxyphylla, Aquilaria sinensis, Epilobium parviflorum and Piper cubeba 
70% EtOH extracts (Fig.4.1C) could reduce LNCaP cell numbers quite significantly. Epilobium 
parviflorum, which was used as a control for the screen, is currently used as a phytotherapy 
against BPH. Therefore, it will not be further investigated.   
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Fig. 4.1 Effects of plants extracted with water (A), 30% EtOH (B) and 70% EtOH on LNCaP cells. 
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Further Piper extractions 
Piper cubeba was extracted using a wider range of ethanol concentrations. According to Fig. 
4.2, extracts made from 50% EtOH onwards started to have antiproliferative effects on LNCaP 
cells. It suggests that the more lipophilic fractions contain more active compounds, which could 
be responsible for the reduced cellular growth. 
  
 
 
 
 
Fig. 4.2 The effects of different Piper cubeba extracts 
on the growth of LNCaP cells. 
 
 
 
 
Selection of plant candidates 
We have decided to use the following plant extracts for further research. 
1. Astra, Water extract of Astragalus membranaceus 
2. Alp, 70% EtOH extract of Alpinia oxyphylla 
3. Aquil, 70% EtOH extract of Aquilaria sinensis 
4. P9605, 96% EtOH extract of Piper cubeba 
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5. Potential hepatotoxicity 
5.1 Introduction 
 
Hepatotoxicity is a common side effect of phyto-medicine. Several medicinal plants (e.g. Kava 
kava) had to be withdrawal from the market because of their association to liver toxicity. We 
decided to test our extracts for potential hepatotoxicity first, before continuing with further 
investigations. 
 
Activity of the mitochondrial electron transport chain and plasma membrane integrity are some 
of the cellular processes influenced by cytotoxic agents. The human hepatocarcinoma HepG2 
cell line is frequently used as an in vitro model for studying hepatotoxicity. A simple 
hepatotoxicity test system measuring the effects of the extracts on the mitochondrial activity and 
plasma membrane integrity on HepG2 cells was therefore performed. 
 
5.2 Materials and methods 
 
Cell culture 
The HepG2 cell line was obtained from the American Type Culture Collection. They were 
cultured in MEM medium containing 1.5 g/L sodium bicarbonate, 1 mM sodium pyruvate and 
10% FBS. The cells were kept in a humidified incubator at 37°C and 5% CO2 and passaged at 
70-80% confluency.  
 
Cytotoxicity assay 
HepG2 cells were seeded 5000 cells/well. After 24 hours of pre-incubation, a range of several 
concentrations per extract was added. After 24 hours, WST-1 was added and incubated for 90 
mins. The absorbance of the yellow formazan dye produced by viable cells was measured at 
450nm with TECAN microplate reader. Terfenadine (100 µΜ, final concentration) served as a 
control. The mitochondrial activity was calculated as a % of the solvent control. 
 
To investigate if the extracts damaged the plasma membrane, the supernatants were tested 
with the Lactate dehydrogenase (LDH) Cytotoxicity Assay Kit (Biovision; Mountain View, CA, 
USA). The principle of this method is based on the measurement of the activity of LDH released 
from cells with damaged plasma membrane. Equal volumes of assay reagent mixture 
(diaphorase/NAD+ and tetrazolium salt INT) were incubated with the supernatant for 10 mins.  
                                                                                                                 Potential hepatotoxcity 
 
 44 
0 10 30 40 50 60 Control
0
25
50
75
100
125
0.0
0.5
1.0
1.5
2.0
2.5
3.0
HepG2
B
Aquil [µg/mL]
M
ito
ch
o
n
dr
ia
l A
ct
iv
ity
 
(%
 
o
f c
o
n
tr
o
l)
Plasm
a
 m
e
m
b
ra
n
e
 Integ
rity
(O
D
 490n
m)
 
TECAN was used to measure the absorbance of the samples at 490 nm. Triton X, which 
destroys the plasma membrane, served as a positive control. Background effect of the extracts 
was also measured for both assays and taken into consideration when evaluating the results. 
 
5.3 Results and Discussion 
 
Potential acute toxicities of Api, Aquil, Astra and P9605 on HepG2 cells were examined after 24 
hours incubated with the cells. All extracts did not disrupt the plasma membrane of the cells as 
indicated from the LDH results. Except for Api, none displayed any significant cytotoxic effects 
even at the highest concentrations tested. Api reduced mitochondrial activity by more than 50% 
between concentrations of 30 to 37 µg/mL.  
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Fig. 5.1 Cytotoxicity data of Api (A), Aquil (B), Astra (C) and P9605 (D). Each graph shows the two parameters 
investigated; mitochondrial activity (Left Y-axis Bars) by WST assay and plasma membrane integrity (Right Y-
axis, Line graph) by LDH assay. The control refers to terfenadine (WST assay) or Triton X (LDH assay). Data 
represent mean ± SD of n≥5.   
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6. Piper cubeba targets multiple aspects of the androgen-signalling 
pathway. 
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6.1 Abstract 
 
Despite the high prevalence of prostate cancer (PC) in the Western world, there is a dearth of 
effective medication. Since the androgen-signalling pathway is very much involved in PC growth 
and development, we investigated the potential of Piper cubeba L. extract, P9605, in targeting 
multiple events simultaneously within this pathway. This may be more effective compared to an 
anti-androgen monotherapy. Our results indicated that P9605 inhibited proliferation in 
androgen-dependent LNCaP human prostate cancer cells by reducing DNA synthesis and 
inducing apoptosis. This anti-growth effect was less pronounced in the androgen independent 
PC-3 prostate cancer cell line. P9605 potently inhibited 5-α reductase II activity, which is 
responsible for converting testosterone to its active form, dihydrotestosterone (DHT), in the 
prostate. It also acted as an antagonist at recombinant wild type androgen receptors (AR). 
P9605 suppressed cell growth and prostate specific antigen (PSA) secretion stimulated by 
physiological concentrations of DHT in LNCaP cells. Interestingly, it down regulated AR levels. 
In conclusion, our findings suggest that P9605 may potentially retard the growth of androgen 
dependent PC via several mechanisms.  
 
Key words: Piper cubeba (L.), Piperaceae, LNCaP cells, apoptosis, 5-α reductase II, androgen 
receptor, PSA. 
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6.2 Introduction 
 
Prostate cancer (PC) is one of the leading causes of cancer-associated deaths among men in 
Western countries. According to the National Prostate Cancer Coalition, over 218,890 new 
cases of PC are forecasted for 2007 in the United States. Several risk factors, responsible for 
the development of PC, are age, race and diet. The early development stages of PC are often 
related to an uncontrollable proliferation of the prostate cells activated by androgens.  
 
There are two major androgens, testosterone and dihydrotestosterone (DHT), in humans. 
Testosterone is the main secretory hormone while DHT is the active form of androgen in 
prostate cells. Androgen deprivation therapy (ADT) is one of the mainstream medical therapies 
[1] employed to treat locally advanced and advanced metastatic PC by drastically reducing the 
production and/or actions of androgens. Treatments include orchiectomy, the use of luteinizing 
hormone-releasing hormone (LHRH) analogues (e.g. leuprolide and goserelin) or LHRH 
antagonists (e.g. abarelix) and anti-androgens [2]. 
 
Although patients show positive response initially to treatment, continuous ADT often results in 
PC progressing to a hormone refractory state within 18-24 months [3]. There are several 
postulated mechanisms explaining the development of ADT resistance. These include somatic 
mutations of the androgen receptor (AR), AR amplification and the development of alternative 
signalling pathways that bypasses the growth and survival promoting function of AR [4]. Defects 
in apoptotic signalling pathways are also common in cancer cells, which enhance tumor 
progression, promote metastasis and therefore develop resistance to various forms of therapy 
[5]. 
 
Considering the essential roles of androgens and AR in PC, it is rational to identify novel agents 
that target multiple aspects of the androgen-signalling pathway. A compound that possesses 
anti-androgenic properties, reduces DHT production, induces apoptosis as well as down-
regulates AR levels may reduce PC growth and its probability of progressing to a hormone 
refractory state.  
 
Plants contain a rich horde of natural substances, which could provide promising bioactive 
candidates. There is some evidence that phytoestrogen (isoflavons, coumestans and lignans) 
may be useful in supporting the treatment of PC [6], [7]. 
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Therefore, the aim of this project was to search for plant extracts with minimal acute and long-
term toxicity, which may help to retard the growth and development of PC. 
 
Piper cubeba L. is indigenous to South of Borneo and Indonesia (Java, Prince of Wales Island 
and Sumatra). The dried unripe fruits possess antiseptic, expectoral and diuretic properties. 
Powdered form or tinctures of the cubebs are used extensively in Indonesia for the treatment of 
gonorrhoea, dysentery, syphilis, chronic bladder inflammation, diarrhoea and asthma [8]. The 
important constituents of cubebs are volatile oil and lignans, which include cubebin, cubebic 
acid and cubeb-resin [9]. 
 
In this study, we investigated the effects of P9605, an ethanolic extract of Piper cubeba L., on 
the growth of 2 human prostate cell lines that represent two different hormonal states of PC and 
its potential anti-androgenic properties. We also hypothesized that cubebin could be an active 
compound (Fig.6.1A) so it was tested alongside with P9605 in several assays. For the first time, 
we report that P9605 has demonstrated the ability to retard androgen dependent cellular growth 
of a PC cell line via several different mechanisms. 
     
 
 
 
Fig. 6.1A Chemical structure of cubebin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.1B A HPLC chromatogram of P9605. Peaks 1, 2 and 4 indicate the presence of lignans based on their typical 
UV spectra. Peak 3 was identified to be cubebin. Based on quantification of the different lignan peak areas, cubebin 
appeared to be the dominant lignan present.  
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6.3 Materials and Methods 
 
Chemicals  
All radioligands (purity > 97%) were purchased from Perkin Elmer (Boston, MA, USA). All cell 
culture mediums, fetal bovine serum (FBS) and the other reagents are of highest quality 
available and were purchased from Sigma (Buchs, Switzerland) if not otherwise stated. 
Charcoal stripped FBS (CSS) was obtained from HyClone (Logan, UT, USA) 
 
Preparation of the extracts 
Piper cubeba L. fruits were provided by Vitaplant AG, Witterswil, Switzerland. The milled seeds 
were de-fatted twice for an hour with hexane in a ratio of 1:5 (w:w) before filtering through an 
AF-6 filter paper (E. Begerow GmbH & Co; Langenlonheim, Germany). The residue was then 
oven dried before being extracted with 96% EtOH in a ratio of 1:5 (w:w).  
 
HPLC analysis  
An aliquot of the extract was analyzed by a Waters HPLC system with UV-VIS detection (280 - 
600 nm) using a Nucleosil 120 – 3, C18 (250 × 4.6 mm) column with a pre-column of the same 
material (both Macherey Nagel; Oensingen, Switzerland) as stationary phase. The mobile 
phase consisted of two solvent systems {A: 0.1% trifluoroacetic acid (TFA) in water (v/v) and B: 
100% acetonitrile in a gradient (0-30 min 90% A, 30-45 min 50% A, 45-46 min 10% A, 46-50 
min 10% A)}. The column temperature was kept at 40 °C and the flow rate was set at 1.0 
mL/min. The detection was carried out at 280 nm and quantification of the lignan in the extract 
was performed by the external standard method using cubebin (Sigma; St-Louis, MO, USA) as 
a reference substance.  
 
Cell culture 
The human prostate adenocarcinoma cell lines LNCaP-FGC and PC-3 were obtained from the 
American Type Culture Collection (Manassas, VA, USA). LNCaP cells were cultured with RPMI 
1640 medium containing 2 mM L-glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 4.5 g/L 
glucose, 1.5 g/L sodium bicarbonate and 10% FBS. PC-3 cells were kept in RPMI medium with 
10% FBS. The cell lines were kept in a humidified incubator at 37 °C and 5% CO2 and passaged 
at 70-80% confluency. Cultures used in subsequent experiments were passaged less than 25 
times. 
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Cellular assays 
Cells were seeded at 5000 cells/well in 96-well plates. After 24 hours of pre-incubation, they 
were treated with 3, 10, 30 µg/mL concentrations of P9605 for an indicated time period unless 
otherwise stated. Phenol red free medium was used for assays performed on LNCaP cells. 
Solvent control, 1% EtOH, was tested in all assays. Cubebin was also tested alongside for 
certain assays 
 
Cytotoxicity assays  
To investigate if the extracts damaged LNCaP cells’ plasma membrane and affected their 
cellular viability, Lactate dehydrogenase (LDH) Cytotoxicity Assay Kit (Biovision; Mountain 
View, CA, USA) and WST-1 (Biovision; Mountain View, CA, USA) were performed respectively 
according to manufacturer’s instructions. Background effects of the extracts were also 
measured for both assays and taken into consideration when evaluating the results. 
 
DNA detection assay 
Cells were treated with P9605 and cubebin for 4-6 days. DNA amount was quantified using 
CyQuant cell proliferation assay kit (Molecular Probes; Eugene, OR, USA) according to 
manufacturer’s instructions. The CyQuant GR dye used in this assay exhibits strong 
fluorescence enhancement when bound to DNA. A range of DNA standards (0-1000 ng/mL) 
was included in every measurement. 
 
3H-Thymidine incorporation assay 
After incubation with the samples, 3H-Thymidine (3 µCi/mL) was added to each well and 
incubated at 37 °C for 3 hours. The cells were then washed and harvested onto filter strips by a 
cell harvester (Brandel Inc; Gaithersburg, MD, USA), and radionucleotide incorporation was 
measured using Tri-Crab 1900 TR scintillating counter (Packard; Meriden, CT, USA). 
 
Apoptosis assay 
After 48 hours of incubation with samples, supernatants of LNCaP cells were assessed by Cell 
death detection ELISAPLUS (Roche; Mannheim, Germany) according to supplier’s instructions. 
The extent of apoptosis was computed as a ratio of the solvent control. 
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 5α Reductase activity 
This assay was preformed using homogenates of HEK293 cells over expressing 5α reductase 
type II. They were purchased from Dr. Hartmann (Department of Pharmaceutical and Medical 
Chemistry, University of Saarbrücken, Germany) [10]. cDNA encoding 5α reductase type II 
were inserted into a pRcCMV vector and expressed in these cells. The samples were pre-
incubated with the cell homogenate (20 µg/mL per assay) for 5 mins at 37 °C. After which, 80 
nM 3H-testosterone (substrate) was added to each well and incubated for 20 mins at 37 °C. The 
remaining 3H-testosterone and new steroids produced were extracted by ethyl acetate. Thin 
layer chromatography (TLC) (equal volumes of cyclohexane and ethyl acetate were used as an 
elution solvent) was preformed to separate the steroids. The TLC plate was then developed 
using a detection spray containing anisaldehyde, concentrated sulphuric acid, acetic acid glacial 
and methanol. To quantify the amount of 3H-testosterone remaining and 3H-DHT produced, 
bands on the TLC corresponding to the respective steroids were cut out and counted via the 
scintillating counter. The activity of the enzyme was determined by calculating the conversion of 
3H-testosterone to 3H-DHT. 
 
Androgen receptor binding 
10, 30, 100 µg/mL of P9605 and 10, 30, 60 µg/mL of cubebin were incubated with recombinant 
androgen receptors (Invitrogen; Carlsbad, CA, USA) and 3H- methyltrienolone (16 nM) at 4 °C 
overnight. To determine non-specific binding, 10 µΜ of non-radiolabelled methyltrienolone was 
used. After incubation, the receptor bound fraction in the assay mix was separated by 
centrifuging through MircoSpin G-25 columns (GE Healthcare; Piscataway, NJ, USA). The 
amount of radioligand bound to the receptors in the filtrate was quantified by the scintillating 
counter.  
 
PSA detection 
LNCaP cells were treated with P9605 and cubebin for 48 hours. After which, the supernatants 
of the cells were removed for PSA quantification. Human PSA ELISA kit (Alpha Diagnostic; San 
Antonio, TX, USA) was used according to supplier’s instructions. The DNA contents of cells 
were determined by the CyQuant cell proliferation assay. The ratio of PSA produced versus 
DNA amount per well was calculated. 
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Western blot analysis  
LNCaP cells were cultured in 25 cm2 cell culture flasks until near confluency (80%) before the 
addition of the samples at concentrations 30, 15, 7.5 µg/mL. After incubation the cells were 
lysed. Equal amounts of cell lysates were mixed with 1x loading buffer (Laemlli Buffer, 5% 2-
mercaptoethanol) and fractionated by electrophoresis on 8% SDS polyacrylamide gels. Proteins 
were electro transferred to nitrocellulose membranes (Millipore; Bedford, MA, USA). Blots were 
incubated overnight at 4 °C with primary mouse anti-human androgen receptor (Progen; 
Heidelberg, Germany) and anti-β-actin (Sigma; MO, USA). The membranes were then 
incubated for 1 hour with secondary goat anti-mouse IgGs conjugated with horseradish 
peroxidase (BioRad; Hercules, CA, USA). The blots were developed with chemiluminescent 
substrate and enhancer (BioRad, Hercules, CA, USA), followed by exposure to x-ray film. The 
images were scanned and analysed by Quantity One software programme (BioRad, Hercules, 
CA, USA). 
 
Statistical analysis 
Each data set represents the means ± standard deviation (SD) of at least 3 experiments. 
GraphPad Software Inc (Prism, version 4, San Diego, CA, USA) was used to calculate the IC50 
values. For repetitive comparison of dose-response data with control values analysis of 
variance (ANOVA) with subsequent Dunnett multicomparison test was used (SPSS for 
windows, version 14.0, SPSS Inc., Chicago, Ill, USA). Statistical significance was established at 
values of p< 0.05. Asterisks (*), (**), (***) indicate p<0.05, p<0.01, p<0.001 respectively.  
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6.4 Results 
 
The anti-proliferative effects of P9605 and cubebin were investigated on androgen dependent 
LNCaP cells and androgen insensitive PC-3 cells. After 4 days of treatment, both P9605 and 
cubebin produced a concentration-dependent reduction of LNCaP cells’ DNA content as 
compared to solvent controls, with IC50 values of 26 µg/mL (Fig. 6.2A) and 18 µg/mL (Fig. 6.2B) 
respectively. At these concentrations, both did not affect the growth of PC-3 cells to the same 
extent. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.2 Antiproliferative effects of P9605 (A) and cubebin (B) on LNCaP and PC-3 cells cultured in 10% FBS 
medium for 4 days. Data represent means±SD of n≥9. DNA content was quantified by CyQuant cell proliferation 
assay *p<0.05 vs control, **p<0.01 vs control, ***p<0.001 vs control. 
 
 
Our HPLC analysis revealed that P9605 consisted of 16.53% of cubebin. We then compared 
the effects of P9605 with the calculated concentration of cubebin present in each dose of P9605 
tested. We could show that 30 µg/mL of P9605 reduced LNCaP growth by 50%. Although in 30 
µg/mL of P9605 there is approximately 5 µg/mL of cubebin, the application of the latter resulted 
in a significantly (p<0.002) lower extend of inhibition of about 25% (Fig. 6.3). Therefore, this 
indicates that there are other constituents in P9605 besides cubebin that may attribute to its 
antiproliferative properties. We have detected three other lignans in our HPLC chromatographic 
fingerprint of P9605 besides cubebin. Although they were present in lower amounts compared 
to cubebin, these lignans could very well be partly responsible for the reduced LNCaP growth 
(Fig. 6.1B).  
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To further confirm that P9605 antagonises androgen-dependent growth, P9605 was incubated 
with and without the addition of 1 nM DHT on LNCaP cells cultured in 10% charcoal stripped 
serum (CSS) medium. Our results showed that P9605 inhibited LNCaP cells’ proliferation when 
cultured in androgen-free medium and P9605 at 10 µg/mL, could significantly (p<0.001) lower 
DHT induced growth by 2-folds (Fig. 6.4A). This proves that P9605 is not weakly androgenic, as 
it did not increase cell growth in the absence of DHT. In fact, it antagonises the proliferative 
effect of DHT. 
 
In addition, we also examined if P9605 reduced DNA synthesis. It inhibited 3H-thymidine 
incorporation with an IC50 value of 11.5 µg/mL (results not shown). 10 µg/mL of P9605 could 
reduce DNA synthesis induced by 1 nM DHT by 50% thus further validating the anti-androgenic 
property of P9605 (Fig. 6.4B). 
Fig. 6.4 LNCaP cells cultured in 10% CSS medium were treated with P9605 in the presence and absence of 1 nM 
DHT for 6 days. Changes in cell numbers were determined by quantifying the DNA content (A). 3H-thymidine 
incorporation was also used to assess the effects of P9506 on DNA synthesis of LNCaP cells kept in 10% CSS 
medium with or without 1 nM DHT (B). Data represent means±SD of n≥5. All data points are expressed as% of the 
solvent controls. *p<0.05 vs control, **p<0.01 vs control, ***p<0.001 vs control. 
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The potential cytotoxicity of P9605 was investigated by observing the effects it had on LNCaP 
cells’ mitochondrial activity and if it induced acute necrosis by destroying the cell membrane 
after 24 hours incubation. WST results showed that only concentrations greater than 40 µg/mL 
were toxic. The LDH assay, in contrast, indicated that no plasma membrane damage occurred 
even at 60 µg/mL. (Fig. 6.5) 
 
 
 
 
 
 
 
 
 
 
 
 
We also investigated if the reduction of cell numbers by P9605 and cubebin could be partly due 
to apoptosis. At 30 µg/mL, P9605 and cubebin increased apoptosis by a factor of 5- and 2-folds 
respectively (Fig. 6.6A). On the contrary, even after 4 days of incubation, at 30 µg/mL, both 
samples did not induce necrosis (Fig. 6.6B). 
 
 
 
 
 
 
 
 
 
 
Fig. 6.6 Apoptotic effects of P9605 and cubebin were assessed on LNCaP cells lysates after 48 hours of treatment. 
DNA fragmentation, a common feature of the late stages of apoptosis was determined from the cell lysates. Values 
were calculated as a factor of the solvent control (A). The possible cytotoxic effects of prolonged incubation of P9605 
and cubebin on LNCaP cells were assessed by LDH assay after 4 days of incubation. Membrane Integrity correlates 
inversely to the degree of necrosis caused by cytotoxicity of the extracts. Membrane Integrity was calculated as a % 
of the control (100% for solvent controls) (B). Data represent means±SD of n=6. *p<0.05 vs control, ***p<0.001 vs 
control. 
Fig. 6.5 Cytotoxicity data of P9605. The 
graph shows the two parameters 
investigated; mitochondrial activity (Left Y-
axis, Bars) by WST assay and plasma 
membrane integrity (Right Y-axis, Line 
graph) by LDH assay. The control refers to 
terfenadine (WST assay) or Triton X (LDH 
assay). Data represents means±SD of n≥8.   
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TNF-α is one of the prime signals that induces apoptosis in a host of cells [11], [12].  We could 
observe this dose-dependent induction of apoptosis by TNF-α in LNCaP cells. We also saw that 
100 nM DHT abolished TNF-α induced apoptosis and lowered the basal level of apoptosis. 
There was a trend that 10 µg/mL of P9605 diminished the anti-apoptotic effect of DHT. 
However, due to the high variability, this effect was not statistically significant (results not 
shown). 
 
It was of interest, as well, to see if P9605 could inhibit DHT synthesis from testosterone. 5α 
Reductase II (5α-RII) is dominantly responsible for converting testosterone to DHT in prostate 
cells. Fig. 6.7A showed that both P9605 and cubebin inhibited 5α-RII activity with IC50 values of 
3.6 µg/mL and 9.9 µg/mL respectively. Finasteride, a well-known 5α-RII synthetic inhibitor, 
served as a control. Its IC50 value of 3.7 nM, derived from our test system also corresponded to 
literature (data not shown) [10], [13].  
 
Androgens mainly elicit their actions when bound to AR. The binding affinities of P9605 and 
cubebin to AR were therefore investigated. IC50 values of P9605 and cubebin derived from 
competitive binding assays using recombinant AR were 58 µg/mL and 25 µg/mL respectively 
(Fig.  6.7B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.7 Effects of P9605 and cubebin on 5α-RII enzyme activity (A). The relative binding affinities of P9605 and 
cubebin to recombinant AR were determined by competitive binding (B). Data represent means±SD of 2 experiments 
preformed in triplicates.  
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Transcription of the PSA gene is positively regulated by the AR [14]. PSA is produced and 
secreted when AR-DHT complex is bound to the specific androgen-responsive elements (ARE) 
on the PSA gene in LNCaP cells. 20 µg/mL of P9605 or cubebin could reduce the PSA levels by 
50% after 48 hours treatment on LNCaP cells (Fig. 6.8A). The dose-dependent increase in PSA 
secretion induced by increasing DHT concentration conforms to literature [15], [16]. As we 
expected, 10 µg/mL of P9605 hindered this trend thus confirming that it antagonises DHT’s 
action. (Fig. 6.8B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6.8 P9605 and cubebin inhibited the secretion of PSA in LNCaP cells. The PSA levels in the cell supernatant 
were measured with the Human PSA ELISA kit after 48h treatment with different concentration of the samples (A). 
The DNA content of each well was determined by CyQuant. The data points were calculated as a ratio of PSA 
secreted to the DNA content of each well. Results represent means±SD of 3 experiments performed in triplicates. 
DHT induced PSA secretion dose-dependently in LNCaP cells and this trend was abrogated in the presence of 10 
µg/mL of P9605. The cells were cultured in 10% CSS medium and treated for 48 hours (B). *p<0.05 vs control, 
**p<0.01 vs control, ***p<0.001 vs control. 
 
 
The reduced PSA secretion could be attributed to several reasons such as P9605 competing 
with natural androgens for the AR or a general reduction in AR levels. To investigate if P9605 
regulates AR levels, LNCaP cells were incubated with the samples before being harvested for 
western blot analysis. As indicated in Fig. 6.9, at 30 µg/mL, both samples reduced AR levels 
significantly after 48 hours. 
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Fig. 6.9 Androgen receptor levels in LNCaP cells were reduced after 48 hours exposure to 7.5, 15, 30 µg/mL of 
P9605 and cubebin. β-Actin was used as a loading control. This change in AR quantity was detected by Western blot 
(n=3). 
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6.5 Discussion 
 
Whilst ADT is a highly successful treatment against hormone-sensitive PC, the onset of 
hormone resistance happens in many cases. This clearly shows that ADT achieved surgically or 
chemically is inadequate. In fact, the treatment “forces” the prostate cancer cells to overcome 
their need for androgen and become androgen-refractory, thus resulting in greater risk of 
morbidity [14]. There are several molecular mechanisms underlying androgen independency. 
Mutated AR are responsible for 10-20% of PC patients [17], [18]. Others include the 
amplification of AR levels and the development of alternative signalling [19], [20]. Hence this 
present study investigates the various abilities P9605 possesses that may potentially help 
control the growth and development of PC more effectively.  
 
LNCaP cells originated from a lymph node metastasis of a PC patient and are perhaps the best-
studied in vitro model for androgen and AR signalling [21]. They express AR as well as 
androgen-inducible genes like PSA, which is a clinical marker for PC [14]. The PC-3 cell line 
was derived from a bone metastasis and they do not possess AR [22]. Both these cell lines are 
therefore quite adequate for our investigation purposes. P9605 suppressed the growth of 
androgen-dependent LNCaP cells more significantly than androgen-insensitive PC-3 cells. This 
suggests that the extract inhibits cell growth fuelled by androgens. Our results have shown that 
besides retarding proliferation by inhibiting DNA synthesis, P9605 also induces apoptosis. We 
also observed a trend where DHT reduced the basal level of apoptosis and that P9605 could 
reverse this anti-apoptotic nature of DHT. Induction of apoptosis is necessary to counter the 
over proliferation of PC cells. 
 
Androgens elicit their various actions when bound to AR. Our competitive binding assays 
revealed that P9605 antagonised the binding of androgens to wild-type recombinant AR. This is 
reinforced by a functional assay. When DHT binds to AR in cells, the bound DHT and AR 
complex translocates to the nucleus and binds to specific ARE on the PSA gene. PSA is then 
produced and secreted. After treatment with P9605, there was a reduction in PSA secretion by 
LNCaP cells. Down-regulation of PSA secretion may also help counter PC growth. PSA has 
been reported to function as a growth factor in LNCaP cells [23], [24] and promote migration 
and metastasis of PC cells through several mechanisms, including the cleavage of insulin-like 
growth factor-binding protein and the degradation of extra cellular matrix proteins [25],[26]. 
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It was also observed that DHT, at a physiological concentration of 1 nM, increased cellular 
numbers and DNA synthesis. DHT also dose-dependently increased PSA secretion in LNCaP 
cells. With 10 µg/mL of P9605, all these effects of DHT were abolished. Hence these evidence 
support the hypothesis that P9605 is anti-androgenic.  
 
Besides antagonising the effects of DHT, P9505 reduced DHT synthesis by inhibiting 5α-RII. 
Reducing the availability of DHT to androgen-dependent prostate cancer cells would restrict its 
growth. 
 
P9605 down regulated AR levels within 48 hours. This is an important observation. Since the 
AR is the main instrument through which androgens elicit their effects, this could explain the 
reduced proliferation levels and PSA secretion. As mentioned before, alterations (mutation, 
changes in quantity) to AR are possible explanations to why hormone resistance develops. 
Reduction of AR levels may therefore retard the growth and development of PC. 
 
Cubebin, despite being a pure substance, proved to be less potent than P9605 in several 
experiments. This is not uncommon. The complex biogenic structure of plant extracts often 
leads to a broader spectrum of pharmacological activity. Interestingly, the concentrations of 
P9605 used in the assays were physiologically relevant. A man of average weight would have 
to consume 4 g of the plant material daily to obtain a blood concentration of roughly 30 µg/mL, 
assuming that absorption is maximum. 
 
In summary, P9605 targets different aspects of the androgen-signalling pathway; reduces DHT 
production, competes with androgens for the AR, prevents DHT from eliciting its actions, inhibits 
PSA secretion and androgen dependent cellular growth, induces apoptosis and down-regulates 
AR levels. The simultaneous occurrence of these multiple actions may be a crucial factor in 
effective PC treatment; the rapid eradication of the cancerous cells by different tactics before 
they could transform and become androgen-independent. 
 
There is still more to be investigated on the other mechanisms of P9605. The pathways, by 
which P9605 induces apoptosis, have not been elucidated yet for example. Further experiments 
should also address the question whether the extract lowers AR levels by reducing its mRNA 
production or speeding up its degradation. Although the initial results obtained in this study are 
very promising, further studies in animals and humans are still required to evaluate the potential 
properties of this extract in vivo.  
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7. 1 Abstract 
 
We have recently shown that an ethanolic extract of Piper cubeba L, P9605, diminished the 
effects of androgens by targeting several aspects of the androgen/androgen-receptor signalling 
pathway. This present study aims to investigate if P9605 also exhibits other interesting features 
such as anti-estrogenic and anti-inflammatory properties.  
 
P9605 significantly retarded growth induced by β-estradiol in MCF-7, a human breast cancer 
cell line. It inhibited aromatase activity, which is responsible for transforming androgens into 
estrogen. Our competitive binding assays also indicated that P9605 binds to both human 
recombinant estrogen α and β receptors. This same extract could prevent the production of 
certain eicosanoids which are inflammatory mediators, by inhibiting the activities of cyclo-
oxygenases, COX-1, COX-2 and 5-lipo-oxygenase (5-LOX) as seen in our enzymatic assays. 
Furthermore, P9605 potently attenuated the induction of interleukin 6 (IL-6), a pro-inflammatory 
cytokine, in differentiated THP-1 cells, which were stimulated with lipo-polysaccharide (LPS).  
 
Taken together with our previous results, P9605 has demonstrated to possess anti-androgenic, 
anti-estrogenic and anti-inflammatory properties. These results support the potential of P9605 
as a phyto-therapy against benign prostatic hyperplasia (BPH).  
 
Key Words: Piper cubeba (L.), Piperaceae, anti-androgenic, anti-estrogenic, anti-inflammatory, 
COX enzymes, 5-LOX, IL-6, aromatase, estrogen receptors, BPH.  
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7.2 Introduction 
 
Benign prostatic hyperplasia (BPH) is the most common neoplasm in aging men. This benign 
proliferation of the stromal and epithelial cells in the prostate increases linearly with age in all 
ethnic groups [1]. The incidence of BPH rises sharply after age 40 and at least 50% of men over 
50 years old suffer from it. 90% of men in their eighth decade of life are said to have histological 
evidence of BPH [2]. 
 
The prostate has four distinct zones: peripheral, central, transition and anterior fibro-muscular 
zone. BPH develops primary within the transition zone (TZ) that surrounds the urethra. The 
enlarging TZ presses against the urethra and bladder, which may lead to annoying lower urinary 
tract symptoms (LUTS) such as urinary hesitancy, urinary retention and increased risk of urinary 
tract infections.  
 
Despite its high prevalence, the reasons why BPH develop remain elusive and it is suggested to 
be of heterogeneous etiology (hormones, age, and inflammation). Although it is still debatable if 
androgens are a causative factor for BPH, they undoubtedly play a role in this disease. Men 
castrated before puberty do not develop BPH. An observation in 1974 indicated that men 
deficient in 5-α-reductase (5α-RII) had hypoplastic prostates [3]. 5α-RII catalyzes the 
conversion of intracellular testosterone to a more active form, dihydrotestosterone (DHT). DHT 
is responsible for the rapid growth and development of the prostate during puberty thus it is a 
prime suspect in BPH.  
 
As men age, the intraprostatic estradiol concentration increases. There is a strong correlation 
between the increasing estradiol:DHT ratio and stromal hypertrophy [4].  Takase et al. have 
detected estrogen receptors and enzymes involved in the estrogen metabolism in human 
prostates [5]. Although the role and mechanism of estrogen in the prostate are still unclear, 
there is growing evidence that estrogen could modify prostatic growth and differentiation. An 
estrogen dominant environment is speculated to increase the production of androgen receptors 
and thus encouraging prostatic growth by over-sensitizing the prostate to androgen [6]. The 
current hypothesis is that the prostate locally produces estrogen that modulates the epithelial 
and stromal cell activity. 
 
Prostatic inflammation is an extremely common histological finding in BPH patients [7]. 
Approximately 5-20% of men diagnosed with BPH suffer from prostatitis-like symptoms [8]. A 
recent study has indicated that the consumption of non-steroidal anti-inflammatory drugs  
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(NSAIDs) is linked with lowered risk developing BPH and LUTS [9]. It is unclear if inflammation 
is the cause or result of BPH but its involvement indicates that anti-inflammatory drugs may help 
to retard development and worsening of the disease. 
 
The current standard BPH medical management strategy is watchful waiting. Many men with 
BPH are asymptomatic, and many others are not bothered by their symptoms. When symptoms 
affect quality of life, pharmacological therapy would include a choice of an α-blocker (terazosin, 
tamsulosin) or/and a 5α-reductase inhibitor (finasteride, dutaseride). BPH patients also 
frequently use phytotherapy, such as saw palmetto, pumpkin seeds, nettle root and African 
plum tree. While some phytotherapy do have comparable efficacy when compared with both 
adrenoceptor blockers and 5α-RII inhibitors, their molecular mechanisms remain to be 
elucidated. 
 
Presently, there is still a lack of preventive medication for asymptomatic BPH against possible 
enlargement of the prostate and development of LUTS. The purpose of this study is to identify 
novel agents that can be used to prevent and/or alleviate BPH. 
 
Piper cubeba L. is indigenous to South of Borneo and Indonesia. The dried unripe fruits 
possess antiseptic, expectoral and diuretic properties. Powdered form or tinctures of the cubebs 
are used extensively in Indonesia for the treatment of gonorrhea, dysentery, syphilis and 
chronic bladder inflammation [10]. The important constituents of cubebs are volatile oil and 
lignans, which include cubebin, cubebic acid and cubeb-resin [11]. 
 
We have demonstrated that P9605, a 96% ethanolic extract of Piper cubeba, has potent anti-
androgenic properties; it prevents the synthesis and multiple actions of DHT (unpublished 
results). This present study was undertaken to investigate if the same extract possesses anti-
estrogenic effects and anti-inflammatory properties as well. 
 
 
 
 
 
 
Fig. 7.1 Picture of the Piper cubeba plant (left) and its fruits (right) 
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7.3 Materials and Methods 
 
Chemicals  
All radioligands (purity >97%) were purchased from Perkin Elmer (Boston, MA, USA). All cell 
culture mediums, fetal bovine serum (FBS) and the other reagents are of highest quality 
available and were purchased from Sigma (Buchs, Switzerland) if not otherwise stated. 
Charcoal stripped FBS (CSS) was obtained from HyClone (Logan, UT, USA) 
 
Plant Material 
Piper cubeba L. fruits were purchased from Alfred Galka GmbH (Gittelde, Germany) and 
identified according to the Deutsches Arzneibuch 6 (DAB 6) by Dr. K. Berger Büter (Vitaplant 
AG, Witterswil, Switzerland). A voucher specimen (ViP_Pipc’03_2) is deposited at Vitaplant AG.  
 
Preparation and analysis of the fluid extract 
Sixty grams of fruits were milled and de-fatted twice with fresh hexane. After filtering through an 
AF-6 filter paper (E. Begerow GmbH & Co; Langenlonheim, Germany), the de-fatted residue 
was then vacuum-oven dried (40°C, 100 mbar) to remove all the hexane before being extracted 
at room temperature (rmt) for 2 hours with 96% (m/m) EtOH in a ratio of 1:5 (w:w).   
 
An aliquot of the fluid extract was analyzed by a Waters HPLC system with UV-VIS detection 
(280 - 600 nm) using a Nucleosil 120 – 3, C18 (250 × 4.6 mm) column with a pre-column of the 
same material (both Macherey Nagel; Oensingen, Switzerland) as stationary phase. The mobile 
phase consisted of two solvent systems {A: 0.1% trifluoroacetic acid in water (v/v) and B: 100% 
acetonitrile in a gradient (0-30 min 90% A, 30-45 min 50% A, 45-46 min 10% A, 46-50 min 10% 
A)}. The column temperature was at 40°C and the flow rate was set at 1.0 mL/min. The 
detection was carried out at 280 nm and quantification of the lignans in the extract was 
performed by the external standard method using cubebin (Extrasynthese; Genay Cedex, 
France) as reference substance. The calculated extract yield of cubebin based on the weight of 
the de-fatted residue was approximately 8%. 
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Cell culture 
The cell lines LNCaP-FGC, MCF-7, MDA and THP-1 cells were obtained from the American 
Type Culture Collection (Manassas, VA, USA). Human prostate adenocarcinoma LNCaP cells 
were cultured with RPMI 1640 medium containing 2 mM L-glutamine, 10 mM HEPES, 1 mM 
sodium pyruvate, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate and 10% FBS. Phenol red free 
Minimum Essential Medium Eagle (MEM) containing 2 mM L-glutamine, 2.2 g/L sodium 
bicarbonate and 10% FBS was used to culture the breast cancer cell lines, MCF-7 and MDA 
cells. THP-1 cells were kept in RPMI 1640 medium containing 2 g/L NaHCO3, 10 mM HEPES, 1 
mM Na-Pyruvate, 30 µM mercaptoethanol and 10% FBS. Normal primary human prostate 
epithelial cells (PrEC) were purchased from CAMBREX Bio Science Walkersville, Inc. 
(Walkersville, MD, USA). These cells were cultured according to the supplier’s instructions. HL-
60 cells (DSMZ; Braunschweig, Germany) were cultured in complete RPMI 1640 medium 
supplemented with 10% FBS. 1% (v/v) penicillin/streptomycin solution was added to all cell 
cultures. The cell lines were kept in a humidified incubator at 37°C and 5% CO2 and passaged 
at 70-80% confluency. Cultures used in subsequent experiments were passaged less than 15-
25 times. 
 
DNA detection assay 
DNA amount was quantified using CyQUANT cell proliferation assay kit (Molecular Probes, 
Eugene, OR, USA). Cells (5000 cells/well in 96-well plates) were treated with P9605 (3, 10, 30 
µg/mL) for 4 days. After incubation with the samples, the medium was discarded and the plates 
were frozen at -80°C. The CyQUANT GR dye used in this assay exhibits strong fluorescence 
enhancement when bound to DNA or RNA. After thawing the plate, the cells were incubated 
with 195 µL of CyQUANT lysis buffer containing DNA-free RNase (1.35 Kunitz units/mL) for 1 
hour at room temperature to eliminate the RNA. 5 µL of CyQUANT GR dye reagent was then 
added to every well and incubated for 5 mins in the dark. TECAN infinite 200 multifunctional 
microplate reader (Tecan; Männerdorf, Switzerland) was used to measure fluorescence with the 
excitation wavelength set at 485 nm and the emission wavelength at 530 nm. The assay was 
linear over a range of 50 to 50,000 cells under these conditions. The DNA quantities were 
calculated using a DNA standard curve. 
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3H-Thymidine incorporation assay 
LNCaP and MCF-7 cells were seeded at 5000 cells/ well in 96-well plates. After 24 hours of pre-
incubation, they were treated with a range of either DHT or β-estradiol concentrations and 10 
µg/mL of P9605. After 72 hours incubation with the samples, 3H-thymidine (3 µCi/mL) was then 
added to each well and incubated at 37°C for 3 hours. The cells were then washed and 
harvested onto filter strips by a cell harvester (Brandel Inc; Gaithersburg, MD, USA), and  
radionucleotide incorporation was measured using Tri-Crab 1900 TR scintillating counter 
(Packard; Meriden, CT, USA). 
 
Aromatase activity 
P9605 samples (3, 10, 30 µg/mL) and formestane (synthetic aromatase inhibitor) were 
incubated with an enzyme/substrate mixture of aromatase, CYP19, (BD Bioscience; Woburn, 
MA, USA) and 3H-androstenedione in the presence of a NADPH regenerating system (BD 
Bioscience; Woburn, MA, USA). Aromatase catalyses the conversion of androstenedione into 
estrone, H20 and formaldehyde. The H20 by-product is radioactive. After 15 mins incubation at 
37°C, the non-metabolised 3H-androstenedione was extracted with dichloromethane for 5 mins. 
After centrifugation (3000 g, 5 mins), the water phase was removed and treated with 2% 
dextrane coated charcoal for 30 mins before centrifugation (4000 g, 10 mins). The supernatant 
was then measured with the scintillating counter. The activity of aromatase per sample was 
measured by determining the amount of radiolabel in the water phase and expressed as a 
percentage of the solvent control. 
 
Estrogen binding 
3, 10, 30, 123 µg/mL of P9605 were incubated with human recombinant estrogen α and β 
receptors (Invitrogen; Carlsbad, CA, USA) and 3H-estradiol (2 nM) at rmt for 3 hours. To 
determine non-specific binding, 10 µΜ of non-radiolabelled β-estradiol was used. After 
incubation, the receptor bound fraction in the assay mix was separated by centrifuging through 
MircoSpin G-25 columns (GE Healthcare; Piscataway, NJ, USA). The amount of radioligand 
bound to the receptors in the filtrate was quantified by the scintillation counter.  
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Cyclo-oxygenase (COX) 1 & 2 assay  
This enzymatic assay was performed on both ovine COX-1 and COX-2 enzymes (Cayman 
chemical; Ann Arbor, MI, USA). The samples were pre-incubated with the individual enzymes 
for 15 mins at rmt before starting the reaction with arachidonic acid (10 µM). Negative controls 
were carried out with denatured enzymes (destroyed by boiling). After 3 mins, the reaction was 
stopped by the addition of acetic acid (1 N). The samples were neutralized with NaOH (1 N) 
before quantifying the prostaglandin E2 (PGE2) produced with Enzyme Immuno Assay (EIA) Kits 
from Cayman. The optical densities (OD) were measured at 415 nm by TECAN reader. The 
quantities were calculated using a PGE2 standard curve. 
 
5-Lipoxygenase-Assay (5-LOX) 
The assay was carried out as described by Bennet et al [12]. Human myeloid leukaemia HL-60 
cells were differentiated for 6 to 8 days with DMSO (1.2% v/v) to induce the expression of 5-
LOX. The activity of 5-LOX was measured by determining the quantity of leukotriene B4 (LTB4) 
produced. Briefly, the differentiated cells were suspended in PBS containing Ca2+ (1 mM) and 
glucose (1 mg/mL) and plated 1 x 106 cells/well in 96-well plates. After pre-incubation with the 
samples for 15 mins, the reaction was started by adding Ca2+ ionophore (4.8 mM) and 
arachidonic acid (9.8 M). Negative controls were carried out without Ca2+  ionophore stimulation. 
The assay mix was incubated for 15 mins at 37ºC and terminated by adding 100 µL methanol 
containing HCl (1 M, 3% v/v). After neutralization with 50 µL PBS and centrifugation (340 x g) 
for 10 mins, the LTB4 concentration in the supernatant was determined with (LTB4) EIA Kit from 
Cayman. The ODs were measured at 415 nm by TECAN reader. The quantities were calculated 
using a LTB4 standard curve. 
 
Il-6 Assay 
IL-6 Cytokine-Assay was performed according to Golenbock et al. [13]. 50 pM/mL of phenol-12-
myristate-13-acetate (PMA) was used to differentiate human THP-1 cells (5 x 105 cells/mL). 
After 3 days, the samples were pre-incubated for 30 mins at 37°C with the differentiated THP-1 
cells before adding LPS (1 µg/mL) to induce IL-6 production. Negative controls were carried out 
with the assay mixture without LPS–stimulation. After 24 hours incubation, the supernatant was 
removed for the quantification of IL-6 with EIA Kit from Cayman. The ODs were measured at 
415 nm by TECAN reader. The quantities were calculated using an IL-6 standard curve.  
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Adrenoceptor Binding 
3, 10, 30, 60, 80 µg/mL of P9605 were incubated with human recombinant α1A adrenergic 
receptors (Euroscreen S.A; Gosselies, Belgium) and 3H-prazosin (2 nM) at 37°C for 30 mins. To 
determine non-specific binding, 10 µΜ of prazosin was used. After incubation, the receptor 
bound fraction in the assay mix was harvested onto filter strips by a cell harvester. The amount 
of radioligands bound to the filter strips was quantified by the scintillating counter.  
 
Statistical analysis 
Each data set represents the means ± standard deviation (SD) of at least 2-3 experiments 
(n≥5). The concentration response values were expressed as a percentage of the solvent 
control. GraphPad Software Inc (Prism, version 4, San Diego, CA, USA) was used to calculate 
the IC50 values. For repetitive comparison of dose-response data with control values analysis of 
variance (ANOVA) with subsequent Dunnett multicomparison test was used (SPSS for 
windows, version 14.0, SPSS Inc., Chicago, Ill, USA). Statistical significance was established at 
values of p<0.05. Asterisks (*), (**), (***) indicate p<0.05, p<0.01, p<0.001 respectively. 
Statistically insignificant data points were not denoted. 
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7.4 Results 
 
The anti-growth effects of P9605 on the 2 hormone-dependent cancer cell lines, LNCaP 
(prostate) and MCF-7 (breast) were investigated. Estrogen receptor negative breast cancer cell 
line MDA and a human primary prostate epithelial cell line PrEC were also tested. 30 µg/mL of 
P9605 significantly (p<0.001) reduced the growth of all cell-lines by at least 50% (Fig.7.2A) 
except the MDA cells. Cytotoxicity tests also revealed that the P9605 concentrations tested 
were not toxic on these cell lines (data not shown). 
 
The growth of both LNCaP and MCF-7 cells are fuelled by DHT and estradiol. We thus decided 
to test if P9605 could antagonise growth induced by these hormones. LNCaP cells exhibited a 
biphasic growth curve with maximum proliferation peaking at 1 nM DHT (p<0.001) and 
regressing at DHT concentrations greater than 1 nM (Fig.7.2B). This behaviour has been 
observed by several other groups [14], [15]. The growth of MCF-7 cells, on the other hand, was 
β-estradiol concentration dependent (Fig.7.2C). P9605, at 10 µg/mL, could reduce hormone-
induced DNA synthesis of LNCaP cells at every concentration and even more potently at MCF-
7 cells. The fact that P9605 did not affect the growth of MDA, which is estrogen–independent, 
further substantiates the possibility that extract counteracts the growth promoting effects of 
estrogens. 
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P9605 reduces the synthesis and action of estrogen 
 
 
 
 
 
 
 
 
Fig. 7.2 Antiproliferative effects of P9605 on LNCaP, MCF-7, MDA and PrEC cells cultured for 4 days (A). DNA 
content was quantified by CyQUANT cell proliferation assay. The DNA content in all cell lines (except MDA) at P9605 
concentration of 30 µg/mL was significantly reduced. *** indicates the statistical significant for all 3 cell lines (except 
MDA). 3H-Thymidine incorporation was used to assess the effect of P9605 on the hormone-induced growth in LNCaP 
(B) and MCF-7(C) cells. The cells were cultured in medium containing 10% CSS in the presence of a range of 
hormone concentrations (DHT or β-estradiol) together with either 10 µg/mL of P9605 or solvent for 3 days. Data 
represent means±SD of 3 experiments. All data points are expressed as % of the solvent controls. *p<0.05 vs control, 
***p<0.001 vs control. 
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Aromatase transforms androstenedione to estrone and testosterone to estradiol. This enzyme 
has been detected in the prostate and is a potential generator of estrogen. P9605 could inhibit 
aromatase activity with an IC50 value of less then 10 µg/mL (Fig. 7.3A). It was also of interest to 
observe if P9605 was able to bind to estrogen receptors. Competitive binding assays were 
performed on human recombinant estrogen α and β receptors and the IC50 values were <100 
µg/mL for both receptors (Fig. 7.3B). 
 
Fig. 7.3 Inhibitory action on aromatase by P9605 (A). Formestane, a well-known synthetic inhibitor, was a synthetic 
control for the enzymatic assay. The binding affinities of P9605 to estrogen receptors (ER) α and β were determined 
by competitive binding assay (B). The highest P9605 concentration significantly inhibited ER-α (p<0.001) and ER-β 
(p<0.01). Data represent means±SD of 3 experiments. *p<0.05 vs control, **p<0.01 vs control, ***p<0.001 vs control. 
 
 
To examine its potential anti-inflammatory effects, we observed the inhibitory effect of P9605 on 
the activities of COX-1, COX-2 and 5-LOX enzymes. Their products, the eicosanoids, are 
involved in the inflammation process and are also implicated in the pathogenesis of a variety of 
human diseases, including cancer. P9605 potently inhibited all 3 enzymes (Fig. 7.4A, B and 
Table 7.1). P9605 was slightly more selectively for COX-2 than COX-1 according to their IC50 
values. Comparing the IC50 values of P9605 on both arachidonic acid-metabolizing enzymes, it 
appeared that P9605 is more effective in reducing 5-LOX’s activity then the cyclo-oxygenases’. 
It must be noted, however, that the activity of cyclo-oxygenases were performed on isolated 
enzymes while 5-LOX’s activity in differentiated HL-60 cells was tested.  
 
Cubebin, on the other hand, had no effects on the cyclo-oxygenases but it inhibited 5-LOX. 
(results not shown). 
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IL-6 is a pro-inflammatory cytokine. It has been detected in epithelial cells of BPH and thought 
to promote the growth and development of BPH by being a growth factor [16]. Differentiated 
THP-1 cells produce IL-6 when stimulated with LPS and our results have indicated that P9605 
could drastically reduce this induction (Fig.7.4C). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7.4 Dose dependent inhibitory effect of P9605 on the activities of isolated COX 1 and 2 (A) *** indicates the 
statistical significant for both cyclo-oxygenases, 5-LOX in differentiated HL-60 cells (B) and the production of IL-6 by 
differentiated THP-1 cells (C). Their products were quantified by EIA kits. Data represent means±SD of at least 3 
experiments. ***p<0.001 vs control. 
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Adrenoceptors are present in the prostatic stroma and are thought to influence the resting tone 
of the smooth muscle with the prostate and bladder neck. There are currently 3 distinct 
subtypes of α1 adrenoceptors; α1A, α1B and α1D have been cloned. The constriction of smooth 
muscle appears to be dominantly mediated by the α1A adrenergic receptors. P9605 appears to 
prevent the binding of prazosin to this receptor with an IC50 value of ∼100 µg/mL (Fig. 7.5). 
 
 
 
 
 
 
Fig. 7.5 The ability of P9605 to bind to human 
recombinant α1A adrenergic receptor was determined 
by competitive binding assay. Prazosin was used as a 
synthetic control for the experiment. The data represent 
means±SD (n=6). ***p<0.001 vs control. 
 
 
 
 
 
Table 7.1 IC50 values of P9605 in the various assays 
 
 
Assay 
IC50  of 
P9605 
95% Confidence 
Intervals of IC50 values 
Synthetic Control IC50 of control 
Aromatase 6.7 µg/mL 5.8 - 7.8  µg/mL Formestane 22 nM 
COX 1 25 µg/mL 20.5 - 30.2  µg/mL Indomethacin 0.02 µM 
COX 2 19 µg/mL 14.5 - 23.7  µg/mL Indomethacin 4 µM 
5-LOX 2.8  µg/mL 2.3 – 3.4  µg/mL NDGA 0.1-0.2 µM 
IL-6 6.9 µg/mL 5.0 – 9.4  µg/mL Dexamethasone 0.1 nM 
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7.5 Discussion 
 
In the present study, we have firstly demonstrated that P9605 reduced cellular growth in all the 
cell lines except MDA. LNCaP and MCF-7 cells possess androgen and estrogen receptors 
respectively and their proliferation is hormone-dependent. P9605 could reduce the enhanced 
DNA synthesis induced by DHT and estradiol in both LNCaP and MCF-7 cells respectively. 
Estrogen receptors (ER) are detectable in LNCaP cells [17], so it would have been possible to 
test if P9605 affected estrogen-induced growth. However, Mulder et al [18] have identified that 
the androgen receptor (AR) in LNCaP cells contains a point mutation in its steroid-binding 
domain (codon 868, Thr to Ala). This defect leads to a change in specificity of the AR. Estrogen 
and some anti-androgens can stimulate LNCaP cell growth rate through the AR activation [19]. 
MCF-7 cells contain both wild type ER α and β [20] therefore it is a better model.  
 
We could only conclude that P9605 reduces estrogen-induced proliferation in MCF-7, inhibits 
aromatase and weakly binds to ERα and β. However, these effects could possibly occur in 
LNCaP cells. On the other hand, although PrEC cells are devoid of AR, their cellular growth was 
reduced by P9605. This indicates that, besides the androgen/AR signalling pathway, other 
mechanisms are involved in contributing to P9605’s anti-proliferative effect. We have also 
recently tested another Piper extract (60% ethanolic extraction) on a well-established in vivo 
model for 5α-reductase inhibition in male rats. There was a dose response inhibition trend and a 
14% inhibition of prostatic growth rate at the highest application dose of 200 mg/kg (results not 
shown). 
 
According to our results, P9605 negatively interfered with the activities of COX-1, COX-2, 5-
LOX and the production of IL-6. In literature, several Piper species have exhibited inhibitory 
activity against at least one of these 2 key enzymes of the arachidonic acid metabolism [21]. 
However this is the first time reported that Piper cubeba could inhibit these enzymes as well. 
We also tested if these anti-inflammatory properties could be attributed to cubebin, the 
dominant lignan present. Cubebin had no effects on the cyclo-oxygenases’ activity but it could 
attenuate the actions of 5-LOX. It appears that other constituents in P9605 besides cubebin are 
responsible for the anti-inflammatory properties.  
 
Several studies have indicated strong correlation between inflammation and BPH. COXs and 
LOXs are expressed in the prostate [22] and they generate eicosanoids, which are involved in 
numerous aspects of inflammatory responses and even in the differentiation of normal and 
tumor cells. Under abnormal circumstances, the over-activity or over-expression of these  
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enzymes could be partly responsible for the LUTS. Therefore, targeting these arachidonic acid-
metabolizing enzymes may be another approach to tackle BPH. 
 
Lymphoid cells such as macrophages and lymphocytes are often found within prostatic stromal 
nodules. They produce growth factors and cytokines such as bFGF, IL-6 and TNF-α [23], which 
may lead to an over-proliferation of prostatic cells. The ability of P9605 to reduce the production 
of IL-6 may help combat prostatic enlargement and inflammation. 
 
The current medical strategy employed to tackle BPH is to relieve the symptoms and reduce the 
size of the prostate. P9605 has proven to possess anti-androgenic (unpublished data) and anti-
estrogenic abilities, which could reduce the growth of the prostate. In addition, P9605’s anti-
inflammatory properties can serve to alleviate the painful symptoms associated with BPH. In 
conclusion, P9605 may be an interesting candidate for further studies in BPH patients.  
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8. Aquilaria sinensis 
  
8.1 Introduction 
 
Aquilaria sinensis originates from the south of China. Its agarwood/resinous heartwood is not 
only a valuable source of incense wood but also used pharmaceutically as an anti-emetic, anti-
tussive and sedative agent as a component of several oriental medical recipes [1].  
One of its active compounds includes the sesquiterpenes such as baimuxinic acid and 
baimuxinal and 2-(2-phenylethyl) chromones [2], [3]. Sesquiterpenes are an important 
constituent of essential oils and they also function as pheromones and juvenile hormones in 
plants. Bioactive sesquiterpenes have been found to be anti-malarial [4] and anti-microbial [5]. 
Since Aquil, a 70% ethanolic extract Aquilaria sinensis, has shown promising results in the initial 
screen and hepatotoxicity experiment, it was further investigated in a series of tests for 
potential, anti-androgenic, anti-estrogenic and anti-inflammatory properties. 
 
                         Fig. 8.1A Some of the sesquiterpenoids isolated from Aquilaria sinensis.  
 
 
 
 
 
 
Fig. 8.1B Pictures of Aquilaria sinensis tree, agarwood and 
dried chips from the agarwood (From left to right) 
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8.2 Materials and Methods 
 
Preparation of the extract 
The dried plant material was milled and extracted with 3 different solvents; ultra pure water, 
30% EtOH (w/w) and 70% EtOH (w/w) in a ratio of 1:10. The mixture was left overnight and the 
liquid fraction was separated from the solid residue by filtering through an AF-6 filter paper first 
and then through a 4-7 µm filter paper. The dried mass content of the liquid extract was then 
determined.    
 
Other assays 
Assays were performed according to methods described earlier. Please refer to chapters 6.3 
and 7.3 for details. 
 
8.3 Results 
 
Aquil antagonises proliferative effects induced by sex hormones 
 
Based on the results from the initial screen, Aquil, the Aquilaria sinensis extract made from 70% 
ethanol significantly reduced LNCaP cell numbers in comparison to the others. This anti 
proliferative effect was further validated by using different assays to assess cell growth; 
measuring the change in DNA content and the incorporation of radioactive thymidine. According 
to the results, Aquil specifically inhibited the growth of both hormone-dependent LNCaP (Fig. 
8.2A) and MCF-7 (Fig. 8.2B) cell lines with IC50 values of ∼11.5 µg/mL and 44 µg/mL 
respectively. It did not significantly reduce cellular growth of the other cell lines. 
 
To substantiate the assumption that Aquil reduced proliferation by preventing the effects of sex 
hormones, LNCaP and MCF-7 cells were incubated with a range of DHT and estradiol 
respectively in the presence of either Aquil or solvent. 10 µg/mL of Aquil, in the absence of both 
hormones, did not increase cellular growth of both cell lines. However, it reduced hormone-
induced DNA synthesis in LNCaP cells at every concentration (Fig. 8.2C) and even more 
potently at MCF-7 cells (Fig. 8.2D). 
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Fig. 8.2. Antiproliferative effects of Aquil on prostatic cell lines LNCaP, PC-3 and PrEC cells (A) and on breast cancer 
cell lines MCF-7 and MDA cells (B). The effects of Aquil on the hormone induced growth in LNCaP (C) and MCF-7 
(D) cells. The cells were cultured in medium containing 10% CSS in the presence of a range of hormone 
concentrations (DHT or β-estradiol) together with either 10 µg/mL of Aquil or solvent for 3 days. Data represent 
means±SD of 3 experiments. 
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Cytotoxicity and apoptotic data of Aquil on LNCaP cells 
 
Aquil exhibited no acute cytotoxic effects on mitochondrial activity and it did not induce necrosis 
even at 60 µg/mL (Fig. 8.3.A). On the other hand, programmed cell death was initiated by 
concentrations between 3 to 10 µg/mL (Fig. 8.3B). At 30 µg/mL, there is a 3-fold increase in 
apoptosis compared to the solvent control. There was a trend indicating that 10 µg/mL of Aquil 
may reverse the anti-apoptotic effect of DHT (Fig. 8.3C). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8.3 Cytotoxicity data of Aquil (A). The graph shows the two parameters investigated; mitochondrial activity (Left 
Y-axis, Bars) by WST assay and plasma membrane integrity (Right Y-axis, Line graph) by LDH assay. The control 
refers to terfenadine (WST assay) or Triton X (LDH assay). Data represents means±SD of n≥8.   Apoptotic inducing 
effects of Aquil were assessed on LNCaP cells lysates after 48 hours of treatment (B). The anti-apoptotic effect of 
DHT in LNCaP cells cultured in 10% CSS medium could be reversed by 10 µg/mL of Aquil (C). DNA fragmentation, a 
common feature of the late stages of apoptosis was determined from the cell lysates. Values were calculated as a 
factor of the solvent control.   
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Aquil reduces the synthesis of DHT and estrogen 
 
As mentioned earlier, 5α-RII is responsible for the conversion of testosterone to DHT and 
aromatase transforms androgens to estrogen. Aquil was able to inhibit 5α-RII and aromatase 
with IC50 values of 20 µg/mL (Fig. 8.4A) and 35 µg/mL (Fig. 8.4B) respectively. 
Fig. 8.4 Inhibitory action on 5α-RII (A) and Aromatase (B) by Aquil. Data represent means±SD of 3 experiments. 
 
 
 
Aquil inhibits secretion of PSA in LNCaP cells  
 
The PSA secretion levels were reduced 50% by 10 µg/mL of Aquil after 48 hours (Fig. 8.5A). 
DHT increased PSA secretion in a concentration-dependent fashion, which is greatly reduced in 
the presence of 10 µg/mL of Aquil (Fig. 8.5B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8.5 Aquil inhibited the secretion of PSA in LNCaP cells (n=3) (A). DHT induced PSA secretion dose-dependently 
in LNCaP cells and this response was abrogated in the presence of 10 µg/mL of Aquil (B). The cells were cultured in 
10% CSS medium and treated for 48 hours (n≥6). The data points are calculated as the ratio of PSA secreted to the 
DNA content of each well.  
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Aquil down regulates AR levels. 
 
Aquil reduced the proliferative and PSA inducing effects of DHT. One postulated mechanism is 
via altering the levels of AR available. As Fig 8.6 indicates, there is a significant reduction of AR 
levels from 30 µg/mL onwards.  
 
 
Fig. 8.6 Western Blot indicating the quantity of AR in 
LNCaP cells after 48 hours incubation with different 
concentrations of Aquil. β-Actin bands act as a 
loading control. (n=2) 
 
 
 
 
 
 
 
 
 
Anti-inflammatory properties of Aquil 
 
Although Aquil had no inhibitory effects on the activity of the cyclo-oxgenases, it specifically 
reduced 5-LOX’s activity  with an IC50 of ∼30 µg/mL. 
 
Fig. 8.7. Dose dependent inhibitory effect of Aquil on the activities of COX 1&2 (A) and 5-LOX in differentiated HL-60 
cells (B). Data represent means±SD of n≥5. 
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8.4 Discussion 
 
Similar to P9605, Aquil has shown to possess anti-androgenic, anti-estrogenic and anti-
inflammatory properties.  
 
In comparison to P9605, 
Antiproliferative abilities: 
Aquil specifically inhibited proliferation of the hormone-dependent cell lines LNCaP and MCF-7, 
while P9605, at 30 µg/mL, significantly (p<0.001) reduced cellular growth of AR-negative PC-3 
and PrEC cells as well. By comparing IC50 values, Aquil proved to more potently exert anti-
proliferative effects on LNCaP than P9605. However P9605 had a stronger effect on MCF-7 
cells.  
 
Cytotoxicity and Apoptotic effects: 
Both extracts do not have any cytotoxic effects on the HepG2 cells, even at 60 µg/mL. While 
this result is also reflective of Aquil on LNCaP cells, P9605 reduces LNCaP cells’ mitochondrial 
activity by 50% at 50 µg/mL. Aquil and P9605 induced apoptosis to a similar extent. 
 
Other assays: 
Aquil, although it inhibited both 5α-RII and aromatase with IC50 values of 20 µg/mL and 35 
µg/mL respectively, was less superior then P9605 (P9605 had IC50 values of 3.6 µg/mL and 6.7 
µg/mL in the 5α-RII and aromatase experiments respectively). On the other hand, Aquil reduced 
PSA secretion more effective then P9605 at the same concentration. Based on the western blot 
results, P9605 downregulated AR levels to a greater degree compared to Aquil at 30 µg/mL. 
 
Anti-inflammatory properties: 
P9605 inhibited the COX 1 & 2 and the 5-LOX activities. Although Aquil had no effects on the 
cyclo-oxygenases, it specifically inhibited 5-LOX.  
  
Taken altogether, Aquil has demonstrated more dominant anti-androgenic than anti-estrogenic 
properties. Cellular assays have hinted that Aquil could more effectively antagonise the 
proliferative and PSA inducing abilities of DHT in comparison to P9605. Considering the ability 
of P9605 to down-regulate the AR levels more effectively than Aquil, it could be hypothesized 
that P9605 reduces the effects of DHT by this mechanism. Aquil, on the other hand, may 
antagonise the actions of androgens by 1) affect the binding affinity of DHT to AR, 2) prevent  
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HSPs from dissociating from the AR; 3) prevent the translocation of the ligand-bound AR to the 
nucleus, 4) affect the co-regulators, thus preventing the transcription process. 
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9. Astragalus membranaceus  
9.1 Introduction 
 
The genus Astragalus consists of about 2000 species of small shrubs. They are more 
commonly known as milk vetch. Astragalus membranaceus (Astragalus M.) is native to northern 
China and the elevated regions of the Chinese provinces, Yunnan and Sichuan. This Chinese 
astragalus species has been most extensively tested, both chemically and pharmacologically. 
According to traditional Chinese medicine, it acts as a tonic to protect the immune system [1]. 
Research has indicated that it enhances the immune response in vivo and in vitro [2], [3], [4]. 
 
Astragalus M. contains numerous components, including flavonoids [5] (e.g. quercetin, 
kaempferol), polysaccharides, triterpene saponins [6]  (e.g. astragalosides I–VII), amino acids, 
and trace minerals. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9.1A Structures of flavonoids (Quercetin, Kaempferol) and Astragalosides. 
 
 
  
 
 
 
Fig. 9.1B Picture of Astragalus membranaceus plant (left) and 
slices of its dried roots (right). 
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9.2 Materials and Methods 
 
Preparation of the extract 
The dried plant material was milled and extracted with 3 different solvents; ultra pure water, 
30% EtOH (w/w) and 70% EtOH (w/w) in a ratio of 1:5. The mixture was left overnight and the 
liquid fraction was separated from the solid residue by filtering through an AF-6 filter paper first 
and then through a 4-7 µm filter paper. The dried mass content of the liquid extract was then 
determined.    
 
Other assays 
Assays were performed according to methods described earlier. Please refer to chapters 6.3 & 
7.3 for details. 
 
 
9.3 Results  
 
Astra inhibits LNCaP proliferation 
The initial screen had indicated that Astra, the Astragalus membranaceus aqueous extract 
significantly reduced LNCaP cell numbers as quantified by the WST assay. This anti 
proliferative effect was further confirmed by measuring another parameter of proliferation, DNA 
content of LNCaP cells after treatment. According to Figs. 9.3A and B, Astra negatively 
influenced the growth of the LNCaP cells with an IC50 value of 20 µg/mL. 
 
Fig. 9.2 Antiproliferative effects of Astra on prostate cell lines (A) and the breast cancer cell lines (B). The data 
represent means±SD of n≥6. 
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Cytotoxicity and apoptotic data of Astra on LNCaP cells 
According to Fig. 9.3A, Astra is not cytotoxic to LNCaP cells even at the highest dose applied. 
At 30 µg/mL, LNCaP cells showed no significant increase in apoptosis (Fig. 9.3B). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9.3 Cytotoxicity data of Astra (A). The graph shows the two parameters investigated; mitochondrial activity (Left 
Y-axis, Bars) by WST assay and plasma membrane integrity (Right Y-axis, Line graph) by LDH assay. The control 
refers to terfenadine (WST assay) or Triton X (LDH assay). Data represent means±SD of n=5 (B). Apoptotic inducing 
effects of Aquil were assessed on LNCaP cells lysates after 48 hours of treatment. (n=6). Values were calculated as 
a factor of the solvent control.   
 
 
Other assays 
As Fig 9.4 indicates, Astra exhibited no effects on the activity of 5α-RII, aromatase, COXs, 5-
LOX, PSA secretion and AR level even at very high doses ≥ 60 µg/mL. 
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Fig. 9.4 Effects of Astra on 5α-RII (n= 6) (A), Aromatase (n=4) (B), COX 1&2 (n=6) (C), 5-LOX (n=6) (D), PSA 
secretion (n=3) (E) and western blot (n=1) (F) 
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9.4 Discussion 
 
Although Astra inhibited LNCaP cell proliferation like its 2 other counterparts, P9605 and Aquil, 
it did not seem to do so via similar mechanisms.  Net changes in the cell numbers depend on 
increase in cell growth or death. Astra is not a potent apoptosis inducer thus programmed cell 
death is not the explanation for the reduced cell quantity as compared to control. One 
hypothesis could be that LNCaP cells when treated with Astra, do not proliferate while those 
treated with solvent increased over time. It might be possible that Astra consists of 
phytochemicals that directly affect the cell-cycle regulation or induce cellular differentiation that 
could stop cells from proliferating. 
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10. Conclusion & Outlook 
 
Androgens are essential for normal prostate growth but they also have a permissive role in the 
genesis of both BPH and PC. Treatments that reduced androgen levels have demonstrated 
limited success in both pathologies. BPH and PC still continue to impose a major healthcare 
problem. It is clear now, that androgens are not solely responsible for these prostate diseases. 
Mounting evidence indicates that estrogens and inflammation are involved as well.  
Our current knowledge of the complex interactions between the androgen, estrogen and 
inflammatory pathways is still in its infancy. However, should further research identify important 
cellular components involved in the cross talk among these pathways, they would certainly be 
potential targets for drug development. 
 
Twenty tropical plants had been screened in this project and 2 plant extracts; Aquilaria sinensis 
(Aquil) and Piper cubeba (P9605), have demonstrated the potential to prevent and/or alleviate 
these two prostatic diseases. According to our investigations, their postulated mechanisms 
include 
 
• reducing the availability of DHT by inhibiting 5α-RII  
• reducing the availability of estrogen by inhibiting aromatase. 
• preventing DHT actions (e.g. DHT induced proliferation and PSA secretion) 
• competing with native ligands (e.g. DHT, estradiol) for the AR and ER. 
• downregulating AR levels. 
• inducing apoptosis 
• reducing the production of inflammatory mediators by inhibiting COXs and/or 5-LOX. 
 
In conclusion, P9605 and Aquil consist of bioactive components that could, not only, target the 
contributing role of the hormonal but also the inflammatory system involved in the etiology of 
BPH and PC.  
 
The outlook for Piper cubeba is very promising; we have already started to initiate animal 
studies. Furthermore, epidemiological studies could also be performed to identify possible links 
between the Piper cubeba consumption and BPH. If results prove satisfactory, P9605 could 
potentially be used as a dietary supplement.  
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Aquilaria sinensis, however, is currently on the list of endangered species. Therefore the large-
scale usage of the plant is understandably not acceptable unless it could be cultivated. 
However, Aquil possesses several active compounds especially the sesquiterpenes, a class of 
terpenes. More in depth research could focus on identifying if sesquiterpenes where responsible 
for the responses we had with Aquil.  
 
Considering the anti-estrogenic properties of P9605 and Aquil, they may also be useful for 
diseases like breast cancer. Their anti-inflammatory properties could nevertheless be 
harnessed for inflammatory diseases such as asthma and arthritis. The possibility if both 
extracts could work in synergy could also be investigated. 
 
There is no magic pill to treat BPH and PC, unfortunately. However, it is highly possible to 
prevent the development and progression of these two prostatic pathologies with adequate 
modifications to diet as observed from epidemiological studies. A plausible future possibility is to 
tailor-make one’s diet together with supplements and medicine according to one’s genetic and 
biochemical status in an attempt to reduce the risk of such diseases. 
 
 
The aim of medicine is to prevent disease and prolong life, 
the ideal of medicine is to eliminate the need of a physician. 
William James Mayo (June 29, 1861 – July 28, 1939) 
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